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Abstract
Adolescents are regarded as a high risk group in South Africa with the highest
human immunodeficiency virus (HIV) incidence occurring in this group. Pre-
vention among adolescents is therefore a key in decreasing the HIV burden.
This thesis aims to assist in the design of trials by simulating the potential out-
comes of a combination prevention trial in adolescents. We develop a stochastic
individual-based model stratified by sex and age. We then use this model to
determine the impact of various prevention packages on HIV incidence among
adolescents participating in a hypothetical trial over a three year period. The
trial that is simulated involves an intervention arm, in which adolescents are
offered a choice of a prevention methods (including medical male circumcision
(MMC), oral pre-exposure prophylaxis (PrEP) and antiretroviral-based vagi-
nal microbicides (ARV-VM)), and a control arm. We predict that the impact
of a full prevention package on HIV incidence would be a 46% per person-
year(PPY) (95% CI 45–47%) risk reduction. The combination of MMC and
PrEP has a substantial impact on HIV incidence in males, with a 51% PPY
(95% CI 49–53%) relative risk of HIV infection. Offering women the choice of
PrEP, a microbicide gel or a microbicide in the form of a vaginal ring would be
less effective, with a 57% PPY (95% CI 56–58%) relative risk of HIV acquisi-
tion. This is not substantially different from the relative risk estimated when
the vaginal ring alone is offered, as the ring is assumed to be the most accept-
ii
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able of the three prevention methods. We determine a sample size requirement
of approximately 1013 in each arm of a trial would achieve 80% power to detect
a statistically significant reduction in HIV risk. We find that the relative risk
is sensitive to the assumed degree of correlation between condom use and the
acceptability of the prevention method. We also find that the most efficient
trial design may be to offer both MMC and PrEP to males but to offer only
a microbicide ring to females. Further work is required to better understand
the processes by which adolescent prevention method choices are made.
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Uittreksel
Adolessente word beskou as ‘n hoe risiko groep in Suid Afrika, met die hoogste
menslike immuniteitsgebrekvirus (MIV) insidensie in hierdie groep. Voorkom-
ing van MIV onder adolessente is daarom noodsaaklik om die MIV las te
verminder. Die doel van hierdie tesis is om te help met die ontwerp van stud-
ies deur die moontlike uitkomste van ‘n kombinasie-voorkoming studie in ado-
lessente te simuleer. Ons het ‘n stogastiese individu-gebaseerde model, gestrat-
ifiseer met betrekking tot seks en ouderdom, ontwikkel. Ons het toe die model
gebruik om die impak van ‘n verskeinheid van voorkomingspakette op MIV in-
sidensie onder adolessente wat deelneem aan ‘n hipotetiese proef oor ‘n drie jaar
periode, te bepaal. Die proef wat gesimuleer word behels a intervensie groep,
waarin die jong volwassenes ‘n keuse van voorbehoedings metodes (insluitende
mediese manlike besnydenis (MMB), pre-blootstelling profilakse (PrBP) en
anti-retrovirale vaginale mikrobisiedes (ARV-VM)) aangebied word, en ‘n kon-
trole groep. Ons voorspel dat die impak van ‘n volle voorkomingspaket op MIV
insidensie ‘n 46% per persoon-jaar (PPJ) (95% VI 47–47%) risiko verminder-
ing sal wees. Die kombinasie van MMB en PrBP het ‘n substansiele impak
op MIV insidensie onder mans, met ‘n relatiewe risiko van MIV infeksie van
51% PPJ (95% VI 49–53%). Om die keuse van PrBP, ‘n mikrobisiede gel of
‘n mikrobisiede in die vorm van ‘n vaginale ring aan vrouens te bied, is min-
der effektief, met ‘n relatiewe risiko van MIV infeksie van 57% PPJ (95% VI
iv
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56%–58%). Hierdie verskil nie substansieel van die beraamde relatiewe risiko
in die geval waar slegs die vaginale ring gebied word nie, aangesien daar aan-
vaar word dat die ring die mees aanvaarde van die drie voorkomingsmetodes is.
Ons het bepaal dat ‘n steekproef van ongeveer 1013 individue in elke arm van
die proef nodig is om ‘n 80% kans te he om ‘n statisties betekenisvolle afname
in MIV-risiko te bespeur. Ons vind dat die relatiewe risiko sensitief is tot die
aanvaarde graad van die korrelasies tussen kondoom-gebruik en die aanvaard-
ing van die voorkomings metodes. Ons het ook gevind dat dit mag wees dat
die mees doeltreffende proef ontwerp is om beide MMB en PrBP vir mans en
slegs ‘n mikrobisiede ring vir vrouens te bied. Verdere werk word benodig om
die prosesse waarby jong volwassenes keuses maak oor voorkomingsmetodes te
verstaan.
Stellenbosch University http://scholar.sun.ac.za
Acknowledgements
I give my sincerest thanks to the Almighty Allah for bestowing His blessings
upon me.
I express my gratitude and thanks to my supervisor, Dr. Leigh Johnson,
for his assistance and guidance throughout my thesis. His patience, teachings
and understanding, together with all the discussions and comments, were most
valuable and beneficial. I thank Prof. Alex Welte for giving me the opportunity
to do this project and for assisting with the supervision of my thesis.
I am indebted to all the staff and students at SACEMA for their contribu-
tions. They have become like a family to me. I cannot say thank you enough
to everyone for their support and motivation, both on an administrative and
a personal level. I express my special thanks and gratitude to Dr. Gavin
Hitchcock and Prof. John Hargrove for their assistance, encouragement and
guidance.
I thank my family and friends for their continuous support. I am especially
grateful to my husband for his unwavering support, patience and love.
vi
Stellenbosch University http://scholar.sun.ac.za
Dedications
To my husband, Basheer Ah Shene, and my family.
vii
Stellenbosch University http://scholar.sun.ac.za
Contents
Declaration i
Abstract ii
Uittreksel iv
Acknowledgements vi
Dedications vii
Contents viii
List of Figures xi
List of Tables xv
1 Introduction 1
2 Literature Review 4
2.1 Sexual Behaviour of Adolescents . . . . . . . . . . . . . . . . . . 4
2.1.1 Age of Sexual Debut . . . . . . . . . . . . . . . . . . . . 5
2.1.2 Sexual Frequency . . . . . . . . . . . . . . . . . . . . . . 6
2.1.3 Partnership Formation and Dissolution . . . . . . . . . . 6
2.1.4 Age-mixing . . . . . . . . . . . . . . . . . . . . . . . . . 7
viii
Stellenbosch University http://scholar.sun.ac.za
CONTENTS ix
2.1.5 Condom Use . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2 Male Circumcision . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.1 Patterns of Male Circumcision Adoption . . . . . . . . . 9
2.2.2 Evidence of Efficacy of Male Circumcision . . . . . . . . 11
2.2.3 Acceptability of Male Circumcision . . . . . . . . . . . . 13
2.2.4 Mathematical Models of Male Circumcision . . . . . . . 15
2.3 Pre-exposure Prophylaxis . . . . . . . . . . . . . . . . . . . . . . 16
2.3.1 Evidence of Efficacy of PrEP . . . . . . . . . . . . . . . 17
2.3.2 Acceptability of and Adherence to PrEP . . . . . . . . . 18
2.3.3 Mathematical Models of Pre-exposure Prophylaxis . . . . 19
2.4 Vaginal Microbicides . . . . . . . . . . . . . . . . . . . . . . . . 21
2.4.1 Efficacy of Vaginal Microbicides . . . . . . . . . . . . . . 22
2.4.2 Acceptability of and Adherence to Vaginal Microbicides . 23
2.4.3 Mathematical Models of Vaginal Microbicides . . . . . . 24
2.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3 Mathematical Model 27
3.1 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2 Modelling the Baseline Characteristics of each Individual . . . . 28
3.2.1 Sex and Age . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.2.2 Age of Circumcision (males only) . . . . . . . . . . . . . 29
3.2.3 Age of Sexual Debut . . . . . . . . . . . . . . . . . . . . 29
3.2.4 Risk Level . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2.5 HIV Status . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2.6 Number of Partners . . . . . . . . . . . . . . . . . . . . . 34
3.3 Modelling the Partner’s Characteristics . . . . . . . . . . . . . . 37
3.3.1 Partner’s Sex . . . . . . . . . . . . . . . . . . . . . . . . 37
Stellenbosch University http://scholar.sun.ac.za
CONTENTS x
3.3.2 Partner’s Age . . . . . . . . . . . . . . . . . . . . . . . . 37
3.3.3 Partner’s HIV Status . . . . . . . . . . . . . . . . . . . . 38
3.4 Modelling Movements Between States . . . . . . . . . . . . . . . 38
3.4.1 The Rate of HIV Infection . . . . . . . . . . . . . . . . . 41
3.5 Model Estimates of HIV Incidence and HIV Prevalence in the
Baseline Scenario . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
4 Clinical Trial Simulation 48
4.1 The Baseline Characteristics . . . . . . . . . . . . . . . . . . . . 48
4.2 The Prevention Methods . . . . . . . . . . . . . . . . . . . . . . 49
4.2.1 Condom Use Consistency . . . . . . . . . . . . . . . . . . 50
4.2.2 Modelling the Acceptability and Uptake of the Preven-
tion Methods . . . . . . . . . . . . . . . . . . . . . . . . 51
4.2.3 Modelling of Adherence to the Prevention Methods . . . 54
4.2.4 Efficacy of the Prevention Methods . . . . . . . . . . . . 55
4.3 Modelling the HIV Incidence in Trial Participants . . . . . . . . 57
4.3.1 Intervention Arm of Trial . . . . . . . . . . . . . . . . . 57
4.3.2 Comparison with the Control Arm . . . . . . . . . . . . 58
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.4.1 Intervention Packages . . . . . . . . . . . . . . . . . . . . 59
4.4.2 Sensitivity Analyses . . . . . . . . . . . . . . . . . . . . . 62
4.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5 Conclusion and Discussion 70
List of References 80
Stellenbosch University http://scholar.sun.ac.za
List of Figures
3.1 The prevalence of male circumcision. The dashed line indi-
cates the function used to relate the probability of being circum-
cised to the age of circumcision and the solid line indicates the
simulated prevalence of male circumcision. A total of 50 000 indi-
viduals were simulated, of which 25 333 were males. . . . . . . . . . 30
3.2 Proportions consisting of sexually experienced individuals.
The red lines and dots relate to females and the black lines and
dots, males. The total simulated population size was 50 000. The
solid lines are the simulated proportions of sexually experienced
individuals at the start of the simulation. The dashed line indicates
the function that was fitted to the data. The dots are data from
the National HIV Communication Survey of 2009 (Johnson et al.,
2010). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.3 The percentage of high risk individuals. The red lines relate
to females and the black lines, males. . . . . . . . . . . . . . . . . . 33
xi
Stellenbosch University http://scholar.sun.ac.za
LIST OF FIGURES xii
3.4 The prevalence of HIV in youth. The red lines and dots relate
to females and the black lines and dots, males. The solid lines are
the simulated HIV prevalence levels at baseline, and the dashed line
indicates the fitted log-normal distribution. The dots are the data
points from the loveLife survey of 2003 (Pettifor et al., 2004a). The
simulated population consisted of 50 000 individuals. . . . . . . . . 35
3.5 A multi-state model of sexual behaviour: used to determine
the number of partners of an individual. . . . . . . . . . . . . . . . 36
3.6 Multi-state model of sexual behaviour and HIV transmis-
sion: (a) Uncircumcised males; (b) Females and circumcised males.
The dashed arrows from life-states in (a) to life-states in (b) indi-
cate male circumcision. . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.7 Simulated HIV prevalence comparisons for males (left) and
females (right): at baseline and at the end of the trial. . . . . . . 45
3.8 HIV incidence comparisons: for males and females between the
STI-HIV Model (Johnson et al., 2012), ASSA2003 Model (Johnson
et al., 2012) and the simulated incidence over a four year period for
the age groups 15–19 and 20–24. . . . . . . . . . . . . . . . . . . . 46
3.9 HIV incidence comparisons: for males and females between the
HSRC 2002–2005 (Rehle et al., 2010) and the HSRC 2005–2008
(Rehle et al., 2010) and the simulated incidence over a four year
period for the age group 15–24. . . . . . . . . . . . . . . . . . . . . 47
4.1 HIV incidence rate: for males, females and in total. The HIV
incidence rates are given per 100 person-years and were determined
for 1000 trial simulations for a sample size of 2000 individuals of-
fered package 1, over a 3 year trial period. . . . . . . . . . . . . . . 60
Stellenbosch University http://scholar.sun.ac.za
LIST OF FIGURES xiii
4.2 Comparison of relative risk estimates for different inter-
vention packages. The mean relative risk of HIV infection was
determined for 1000 trial simulations for a sample size of 2000 in-
dividuals over a 3 year trial period. . . . . . . . . . . . . . . . . . . 61
4.3 Comparisons of the mean relative risk estimates for in-
dividual prevention methods: for males (above) and females
(below). The mean relative risk of HIV infection was determined
for 1000 trial simulations for a sample size of 2000 individuals over
a 3 year trial period. . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.4 Comparisons of relative risk estimates for different sample
sizes: for males, females and in total. The RRs are determined for
1000 trial simulations for each of the sample sizes of 500 and 2000
individuals over a 3 year trial period. The confidence intervals are
calculated from the 2.5 and 97.5 percentiles of the distributions of
simulated RR values. . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4.5 Comparison of the relative risk estimates when assuming
negative correlation and when assuming positive correla-
tion, between the level of condom use and the level of
acceptability of other prevention methods. In each, we sim-
ulated 1000 trial simulations for a sample size of 2000 individuals
over a 3 year trial period for a full package. . . . . . . . . . . . . . 66
Stellenbosch University http://scholar.sun.ac.za
LIST OF FIGURES xiv
4.6 Comparison of the relative risk estimates when assuming
negative correlation and when assuming positive correla-
tion, between the level of condom use and the level of
acceptability of PrEP. In each, we simulated 1000 trial simula-
tions for a sample size of 2000 individuals over a 3 year trial period
for the single prevention method, PrEP. . . . . . . . . . . . . . . . 67
Stellenbosch University http://scholar.sun.ac.za
List of Tables
2.1 Multiple partnerships over the past year and condom use at last
sex for different age groups, as reported by the various surveys. . . 8
2.2 Relative risk of HIV infection in circumcised men compared to un-
circumcised men, based on three randomized controlled trials. . . . 13
2.3 Adherence levels to PrEP as measured in four randomized control
trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
3.1 The parameter estimates for the baseline characteristics of each
individual’s HIV status used in equation (3.2.4). . . . . . . . . . . . 34
3.2 Parameter estimates used to determine the steady-state distribu-
tion of the number of partners used in equations (3.2.7)–(3.2.9). . . 37
4.1 Summary of parameter estimates used to determine each individ-
ual’s level of acceptability and adherence, and the efficacy of the
prevention methods when assuming complete adherence. . . . . . . 56
4.2 The different prevention methods included in the various packages
used in the model. . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
xv
Stellenbosch University http://scholar.sun.ac.za
LIST OF TABLES xvi
4.3 Results of the measure of “synergy” measuring the interaction be-
tween condoms and PrEP when we assume positive or negative
correlation between condoms and the acceptability of PrEP, based
on equation (4.4.2). . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Stellenbosch University http://scholar.sun.ac.za
Chapter 1
Introduction
South Africa has one of the highest HIV prevalence levels in the world, with
the highest HIV incidence rates occurring in young people (UNAIDS, 2010).
Adolescents therefore must be key targets in preventing the spread of HIV
at a population level. During adolescence, many biological, physical and be-
havioural changes take place. These factors, together with peer pressure and
socio-economic challenges, can result in poor decision making regarding sex.
Lack of condom usage, multiple partners and intergenerational sex, are a few
of these choices that account for the increased risk of acquiring HIV.
The range of possible biomedical HIV prevention methods has advanced
considerably over the last decade. HIV prevention methods now include medi-
cal male circumcision (MMC), pre-exposure prophylaxis (PrEP) and antiretroviral-
based vaginal microbicides (ARV-VM). Randomized controlled trials (RCTs)
have already shown MMC to be effective in reducing the risk of acquiring
HIV (Mills et al., 2008). Both PrEP and ARV-VM are currently undergoing
evaluation to determine levels of efficacy as HIV prevention methods (Abdool
Karim et al., 2010; Thigpen et al., 2012; Baeten et al., 2012). Although RCTs
are the so-called gold standard for demonstrating the efficacy/effectiveness of
1
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 1. INTRODUCTION 2
a prevention method, not all trials produce conclusive or positive results, and
trials are costly to conduct and require numerous resources. To minimize the
risk that a trial produces inconclusive or negative results, the careful design of
the trial is essential. Mathematical modelling is often important in helping to
inform the design of a trial.
Mathematical modelling plays a vital role in understanding HIV/AIDS
epidemiology (Garnett, 2002; Auvert et al., 2000). Modelling the population
level impact and cost-effectiveness of an HIV prevention method helps to in-
form policy (Pretorius et al., 2010; Hankins et al., 2009; Cremin et al., 2011).
Modelling is particularly useful in evaluating the likely impact of a combination
of prevention methods, showing how results might vary depending on levels
of acceptability, product adherence and whether there would be synergy or
antagonism between prevention methods. Modelling is also important in the
context of trial designs for multi-component prevention methods, identifying
the intervention components that are most critical to maximizing effective-
ness and assisting in determining a sample size that is needed to achieve an
adequately powered trial.
Most previous HIV prevention trials and studies have focused on adults,
and it is unclear how far conclusions can be extended to adolescents as ado-
lescents are behaviourally and biologically different from adults. More than
one adolescent-tailored prevention method option is required to address the
diverse needs and unique challenges of HIV prevention in adolescents. The
National Institutes of Health (NIH) in the U.S. is funding exploratory work in
South Africa to evaluate multi-component prevention programmes in adoles-
cents, with a view to possibly conducting a randomized trial of such a multi-
component prevention package. This thesis will assist in the consideration of
Stellenbosch University http://scholar.sun.ac.za
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this trial.
The aim of this thesis is to determine the potential impact of an HIV inter-
vention package on HIV incidence for adolescents in a trial setting, based on
a mathematical model. Prevention methods that are considered for inclusion
in the package are MMC, ARV-VM for females and PrEP. Comparisons of
the impact of different permutations of these prevention methods will assist in
identifying which prevention methods should be included in the ideal package.
The thesis is structured as follows. Chapter 2 reviews the literature on
adolescent sexual behaviour and the HIV prevention methods considered in
this thesis, including MMC, ARV-VM and PrEP. In Chapter 3 we explain the
mathematical model we developed. We demonstrate how the characteristics of
each individual, as well as the partner’s characteristics, are simulated. With
HIV incidence being one of the main outputs of the model, we show the calibra-
tion of the model by comparing the simulated HIV incidence to South African
HIV incidence data. The impact of the prevention package on HIV incidence
is presented in Chapter 4. We present the relative risk of HIV infection for
different prevention packages and evaluate the sample size requirements. We
conclude the thesis with a discussion in Chapter 5 of the findings, as well as
the strengths and limitations of the model.
Stellenbosch University http://scholar.sun.ac.za
Chapter 2
Literature Review
In this section, we outline and review previous studies and models that focus
on adolescent sexual behaviour and the various prevention methods under
consideration. The main objective of the review is to identify the data sources
that are most relevant in estimating the parameters used in the model.
2.1 Sexual Behaviour of Adolescents
Development factors, such as neurobiological and biobehavioural, that occur
during adolescence, result in an increase in risk behaviour, difficulties control-
ling behaviours and emotions, and the pressure to assert individuality (Rivers
and Aggleton, 1998; Wilson et al., 2010). Heterosexual transmission is the most
common mode of HIV transmission among adolescents (Shisana et al., 2009).
Some key drivers of HIV transmission in adolescents are early age of sexual
debut (McGrath et al., 2009); inconsistent condom usage (Katz and Low-Beer,
2008; Pettifor et al., 2004a); sex with multiple or concurrent partners (Ferry
et al., 2001; Johnson et al., 2009); and intergenerational sex (Chapman et al.,
2010).
4
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Studies and models that help to inform model parameters, such as the
rate of partnership formation, the propensity for concurrent partnerships, the
duration of a partnership, the rate of partnership dissolution, sexual frequency
and condom usage, are reviewed below.
2.1.1 Age of Sexual Debut
An early age of sexual debut means a larger probability of possible exposure
to HIV. The percentage of adults who have had sex before the age of 15,
reported by the HSRC National Household Survey of 2008, is 11.3% for males
and 5.9% for females (Shisana et al., 2009). Based on the Second National
HIV Communication Survey (NCS) of 2009, Johnson et al. (2010) reports
these percentages as 14% for males and 5% for females. Johnson et al. (2010)
also reports the average age of sexual debut for 16–24 year olds as 16.3 and
17.2 for males and females, respectively. A 2003 national survey (Pettifor
et al., 2004a) reports similar ages for the mean age of sexual debut, 16.7 for
males and 17 for females. The method to estimate these ages of sexual debut
was based on face-to-face interviews which are subject to social desirability
bias. The average age of sexual debut is likely to be exaggerated, especially in
females (Mensch et al., 2003).
The age of sexual debut is strongly associated with the level of risk be-
haviour in sexually experienced individuals. The younger the age of sexual
debut, the higher the level of risk behaviour of the individual (Eaton et al.,
2003; Pettifor et al., 2005, 2007; Wilson et al., 2010).
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2.1.2 Sexual Frequency
In the National Survey of HIV and Sexual Behaviour Among 15–24 Year Olds,
of the individuals who reported having had sex in the past year , 51% of the
males and 50% of the females said they had had sex 1–5 times in the last month
(Pettifor et al., 2004a). In a study by Kelly (2000), the author collected data
using a questionnaire from a sample of 618 individuals in the 15–30 year age
group from various sites in South Africa. Results from this study showed that
the average number of days an individual had sex in the last 4 weeks, was 3
in non-cohabiting relationships. These studies suggest a low frequency of sex
in youth in the South African context.
2.1.3 Partnership Formation and Dissolution
Multiple partnerships contribute greatly to the transmission of HIV. All three
surveys report on multiple partnerships (more than 1 partner) over the past
year. These are listed in Table 2.1. Across these three surveys, males were
3–5 times more likely to report multiple partnerships than their female coun-
terparts.
Although many studies report numbers of partners, few report rates of
partnership formation and few address the problem of social desirability bias.
The HIV/AIDS model by Johnson et al. (2009), calibrated to the reported
numbers of current sexual partners in the 2005 HSRC national household sur-
vey, estimated the rates of non-marital relationship formation using a Bayesian
approach that took into account social desirability bias in reporting of current
partner numbers. The authors found that the social desirability bias in report-
ing of multiple partners was much greater for females than for males, so the
differences in numbers of partners reported by young men and young women
Stellenbosch University http://scholar.sun.ac.za
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might be a poor reflection of the actual gender differences in rates of partner
change.
A median relationship duration of 9 months (IQR 0.5–24 months) was
reported by women in a study by (Jewkes et al., 2001). Another study by
Pettifor et al. (2005) reported somewhat shorter average partnership durations.
There may be a bias in these studies because people will tend to report on the
duration of their main relationship, not on that of their casual or secondary
partnerships, which would typically be of shorter duration.
Marriage occurs at a relatively late age in SA, when compared with other
African countries (Bongaarts, 2007). In this discussion (and in our model) of
adolescent sexual behaviour, we therefore focus on non-marital relationships.
2.1.4 Age-mixing
A key driver of HIV transmission is age-disparate relationships (Chapman
et al., 2010). Data reported on sexual partnerships generally indicate that
females tend to have older male partners and males tend to have younger
female partners (Pettifor et al., 2004a). Young women with older partners
place themselves at higher risk as they are exposed to an HIV prevalence
level that is higher than that of males of their own age group. Shisana et al.
(2009) found that 15–19 year old males reported a partner age within 5 years
of their own age, in 98.5% of cases. For females, this proportion was much
lower, 72.4%, with a substantial percentage, 27.6%, of females having partners
5 or more years older than themselves. In the NCS survey of 2009, Johnson
et al. (2010) reported that older males tended to have partners who were 5 or
more years younger, when compared to the younger males. Females in the age
group 16–24 years generally had partners 5 or more years older. Pettifor et al.
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(2004a) reported the average partner age difference for young females to be 4
years older.
Table 2.1: Multiple partnerships over the past year and condom use at last sex for
different age groups, as reported by the various surveys.
Survey Age
group
Sex More Than 1
Partner Over
the Last Year
(%)
Condom
Use at Last
Sex (%)
Pettifor et al. (2004a) 15–19 Male 43 57
Female 15 55
20–24 Male 45 57
Female 10.0 44
Shisana et al. (2009) 15–24 Male 30.8 87.4
Female 6 73.1
25–49 Male 14.8 56.4
Female 3.0 58.1
Johnson et al. (2010) 16–19 Male 29 75
Female 9 63
20–24 Male 16 68
Female 2 49
2.1.5 Condom Use
Condoms are one of the most effective ways to prevent the spread of HIV
(Pinkerton and Abramson, 1997). Their efficacy is dependant on the correct
and consistent use of condoms.
The various surveys listed in Table 2.1 shows a generally high level of con-
dom usage at last sex. These reported levels are subject to social desirability
bias as the levels of condom usage are those reported by respondents in face-
to-face interviews. There is a slight decrease in condom usage at last sex from
the 15–24 year age group to the 25–49 year age group (Shisana et al., 2009)
and from the 16–19 year age group to the 20–24 year age group (Johnson
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et al., 2010) for both males and females. Although the proportion of youth
who reported using condoms at last sex is high, there is a great variation in the
consistency of condom use. For example, in the 2003 national survey (Pettifor
et al., 2004a), 33% reported always using a condom, while 31% reported never
using condoms.
2.2 Male Circumcision
Male circumcision is a surgical procedure that involves the removal of the fore-
skin of the penis. It is one of the most commonly practised surgical procedures
in the world and it is estimated that approximately 30% of the global male
population is circumcised. This estimation is based on males aged 15 years
and older (WHO/UNAIDS, 2008). There a two types of circumcisions, namely
therapeutic and non-therapeutic circumcisions. Therapeutic circumcisions are
performed to treat an underlying pathological process and non-therapeutic
circumcisions are performed for social, cultural, religious, hygienic and pro-
phylactic reasons (Perera et al., 2010).
2.2.1 Patterns of Male Circumcision Adoption
Factors influencing the prevalence of male circumcision include religion, cul-
ture, tradition and hygiene. Muslims are the largest religious group to practice
this procedure, followed by Jews. Circumcision among these groups takes place
between birth and puberty. Most neonatal and pre-puberty circumcisions take
place in a clinical setting which provides a safer environment and very few
post-operative complications.
Connolly et al. (2008b) analysed the demographic and behavioural factors
that are associated with male circumcision (based on a national survey in
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2002 in South Africa). The authors found that male circumcision was associ-
ated with increasing age, black race, religious affiliation, home language and
province. Among black South Africans, the median age of male circumcision
was 18 years of age. The ethnic groups that practice traditional male circum-
cision most frequently include the IsiXhosa-speaking, the Setswana-speaking,
the Sepedi-speaking, the IsiNdebele-speaking and the Tshivenda-speaking peo-
ple. These ethnic groups view the practice of male circumcision as a rite of
passage to manhood and circumcision is thus performed mainly on the youth
(Connolly et al., 2008b). The IsiZulu-speaking people stopped the practise dur-
ing the Zulu wars that took place in the early 19th century (WHO/UNAIDS,
2008). Traditional circumcisions are mainly performed in non-clinical settings
where conditions may be unhygienic. The process is performed by medically
untrained people who often work with unsterilised equipment. Safety is thus
a major concern under these conditions as many serious complications have
been reported, even death in some cases (WHO/UNAIDS, 2008). Circum-
cision is more common in the Gauteng, Limpopo, Mpumalanga and Eastern
Cape provinces (Connolly et al., 2008b).
Thomas et al. (2011) shows that self-reporting on male circumcision sta-
tus could exaggerate the actual prevalence of male circumcision. Some men
reported being circumcised, but when they were physically examined, it was
found that they were either not circumcised or only partially circumcised.
Partial male circumcision would not have the same efficacy as complete male
circumcision. Ethnicity is a key determinant in the prevalence of male circum-
cision , with Isi-Xhosa speaking males having a prevalence of 64.3% and more
than 89.1% of them being circumcised after the age of 17 (Connolly et al.,
2008b).
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2.2.2 Evidence of Efficacy of Male Circumcision
The foreskin of the male penis contains a large number of Langerhans cells.
These cells are professional antigen presenting cells lining the mucosal tissue
of the foreskin and form a protective barrier against infection by internalizing
the virus into Birbeck granules where the virus is degraded. If the protective
barrier is breached, the Langerhans cells become productively infected. These
activated cells then migrate to the lymph nodes where they transmit the virus
to the T-cells. The Langerhans cells are the main target of HIV, as they trans-
mit the virus to the T-cells. Also, pre-existing co-infection of the Langerhans
cells with other STIs changes the functionality of the Langerhans cells, thereby
increasing the risk of the HIV infection (de Jong and Geijtenbeek, 2008).
For more than a decade, it has been suggested that male circumcision may
be important in reducing the spread of HIV infection (Moses et al., 1994, 1998;
Seed et al., 1995). Observational studies that include male circumcision as a
risk factor for HIV infection support this premise and have provided substan-
tial evidence that male circumcision may provide a degree of protection against
HIV infection (Weiss et al., 2007). Systematic reviews and meta-analyses
of observational data in sub-Saharan Africa clearly indicate that there is a
strong association between circumcision and a lower prevalence of HIV infec-
tion. Weiss et al. (2000) showed a significant reduction in HIV risk associated
with male circumcision(RR = 0.52, 95% CI 0.40–0.68) with an adjusted risk
ratio of 0.42 (95% CI 0.34–0.54). A multicentre study on the factors deter-
mining the rate of spread of HIV infection was conducted in four cities with
contrasting levels of HIV prevalence in sub-Saharan Africa, namely Kisumu
(Kenya), Ndola (Zambia), Cotonou (Benin) and Yaoundé (Cameroon) (Buvé
et al., 2001a). In this study it was concluded that male circumcision provided
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a protective effect against acquiring HIV infection and it was suggested that
circumcision should be considered as an intervention strategy to help reduce
the spread of HIV (Buvé et al., 2001b). Confounding factors, such as sex-
ual behaviour, social and economic circumstances and STIs, were taken into
account and a multi-variate analysis of circumcision as a risk factor of HIV
infection was conducted in Kisumu (Auvert et al., 2001). This analysis found
that there were two factors that significantly affected the probability of HIV
transmission during sex: circumcision and co-infection with HSV-2 infection.
Randomized controlled trials provide the strongest evidence that male cir-
cumcision is effective. The ANRS1265 randomized controlled trial was carried
out in Orange Farm, South Africa (Auvert et al., 2005). Men aged 18-24
years were randomized to an intervention or a control group. The men in the
intervention group were circumcised immediately. The relative risk of HIV ac-
quisition in the intervention group was 0.40 (95% CI 0.24–0.68) corresponding
to a protection of 60% (95% CI 0.32–0.76). In another randomized trial in
Kisumu, Kenya, men aged 18–24 years were recruited (Bailey et al., 2007).
The trial was stopped 16 months after enrolment because of the significant
reduction in HIV incidence in the circumcision group. In another random-
ized controlled trial in Rakai, Uganda, Gray et al. (2007a) studied men aged
15–49 years. This trial was also terminated early due to the reductions in
HIV incidence in the intervention arm. The protective effect of male circum-
cision against HIV acquisition was estimated to be 51% (95% CI 16–72%).
The adverse events that occurred in the 3 trials were all resolved with medical
treatment. A meta-analysis of these randomized controlled trials showed an
average relative risk of 0.44 (95% CI 0.33–0.60) (Mills et al., 2008). Table 2.2
is a summary of the reduced risk associated with male circumcision found in
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the three randomized controlled trials.
Table 2.2: Relative risk of HIV infection in circumcised men compared to uncir-
cumcised men, based on three randomized controlled trials.
Study Location Relative Risk
(95% CI)
Effectiveness
(95% CI)
Auvert et al. (2005) Orange
Farm, S.A.
0.40 (0.25-0.70) 60% (32%-76%)
Gray et al. (2007a) Rakai,
Uganda
0.49 (0.30-0.83) 51% (16%-72%)
Bailey et al. (2007) Kisumu,
Kenya
0.47 (0.28-0.78) 53% (32%-77%)
A concern regarding the introduction of male circumcision as an interven-
tion strategy is that circumcised men may believe that circumcision protects
against acquiring HIV (Lagarde et al., 2003) and thus increase their sexual risk
behaviour. This risk compensation could then offset the benefits of circumci-
sion and is an important factor to consider when promoting circumcision as an
intervention (Hallet et al., 2008). There is also concern that male circumcision
might increase the HIV infection risk if sexual intercourse is resumed before
wound healing.
2.2.3 Acceptability of Male Circumcision
Acceptability of medical male circumcision is highly variable. Acceptability of
medical male circumcision among Xhosa speakers, who traditionally practise
male circumcision as a rite of passage into manhood, is very low (Rennie et al.,
2007; Mark et al., 2012). A study by Rain-Taljaard et al. (2003) investigates
the potential acceptability of male circumcision as an intervention against HIV
in population with a high HIV prevalence in South Africa. In the analysis, of
the males aged 13–24 years, 59.9% said they would get circumcised if it was
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shown to decrease the chance of getting HIV and STDs. A review done by
Westercamp and Bailey (2007) on the acceptability of male circumcision in
Africa found that the median proportion of uncircumcised men willing to be
circumcised was 65% (range 29–87%). Over 50% of men participating in a
community-based cross-sectional study conducted in the Westonaria District
of South Africa showed willingness to be circumcised (Lagarde et al., 2003).
This percentage increased to 72.5% if male circumcision were to protect against
acquiring HIV/STDs.
The previous studies evaluated stated acceptability, which may differ from
actual uptake. As part of the HVTN503 vaccine efficacy trial, male circum-
cision was offered as an HIV prevention option (de Bruyn et al., 2009). Of
the uncircumcised males, aged 18–35 years, in the study, 33% accepted the
offer to get circumcised. In another South African study of men aged 15–49
years conducted by Lissouba et al. (2011) in Orange Farm, the uptake of male
circumcision was 58.8%.
The age at circumcision would greatly affect the impact of male circumci-
sion on HIV incidence (Londish and Murray, 2008; White et al., 2008). West-
ercamp and Bailey (2007) found the age of circumcision preferred by parents
to be either at birth or around puberty and adolescence, and that acceptability
among youth was more positive than in older adults. Women appear to have
considerable influence on male circumcision, whether it is to circumcise their
sons at birth or to influence their partner’s decision to circumcise. Wester-
camp and Bailey (2007) found that 69% (range 47–79%) of women favoured
circumcision for their partners and 71% (range 50–90%) of women were willing
to circumcise their sons. Lagarde et al. (2003) found that 13% of men reported
they were circumcised because their partner requested it.
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2.2.4 Mathematical Models of Male Circumcision
Various mathematical models have been developed to evaluate the impact of
male circumcision on HIV incidence and prevalence. Increased coverage of male
circumcision results in a greater reduction in HIV incidence (Hallet et al., 2008;
Nagelkerke et al., 2007; White et al., 2008; Williams et al., 2006), but it would
take more than ten years to observe the full effect. When investigating tar-
geting male circumcision at adolescents or youth, Londish and Murray (2008)
found that targeting 10–15 year old males would not have a massive impact
on HIV incidence in the short term, as most in this age group are not sexually
active. Targeting either 15–20 or 20–25 year old males would have much more
of an impact (Londish and Murray, 2008; White et al., 2008). These are the
only studies that have considered the effect of targeting MMC promotion to
adolescent or young age groups.
Combining male circumcision with other prevention methods, like condoms,
has been shown to have a greater impact on HIV incidence than male circum-
cision alone (Podder et al., 2007). Behavioural change and male circumcision
in combination, also yields a greater impact (Hallet et al., 2008). Alsallaq
et al. (2013) predicts a potential for synergies between three prevention meth-
ods (MMC, ART and home-based HIV counselling and testing). The authors
report a combined reduction in HIV incidence in Kwazulu-Natal, South Africa,
of about 50% over a 4 year period. In another model also focussing on the HIV
incidence in KwaZulu-Natal, South Africa, Cremin et al. (2013) demonstrated
a greater decline in HIV incidence when modelling the impact of a combination
of MMC with PrEP and early ART (but at very high coverage levels), than
what was expected from the individual prevention methods.
Several modelling studies have evaluated the potential effect of risk com-
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pensation in circumcised men. Risk compensation, behavioural disinhibition
and a decrease in condom use could all negate the effect of male circumcision
on HIV incidence (Gray et al., 2007b; Hallet et al., 2008; Nagelkerke et al.,
2007; White et al., 2008). Behavioural disinhibition could also directly affect
women and potentially result in an increase in HIV incidence in women (Hallet
et al., 2008; Dushoff et al., 2011). However, in most simulations in which little
or no risk compensation is assumed, the effect of male circumcision on HIV
incidence rates in women is positive (Alsallaq et al., 2009).
2.3 Pre-exposure Prophylaxis
Pre-exposure prophylaxis (PrEP) is the prophylactic use of antiretroviral drugs
(ARVs) by HIV-uninfected individuals in an attempt to prevent HIV acqui-
sition. The idea behind PrEP is to prevent HIV from replicating after an
exposure to an HIV transmission event, thus decreasing the probability of
HIV establishing permanent infection.
ARVs are currently being given to HIV-infected pregnant women before
and during birth, as well as to neonates, in order to prevent mother to child
transmission (PMTCT) of HIV. ARVs are also used as post-exposure prophy-
laxis (PEP) by health-care workers after percutaneous exposure to HIV, to
reduce the risk of HIV transmission (Cardo et al., 1997). Tenofovir Diso-
proxil Fumarate(TDF) and Emtricitabine (FTC), as well as combination of
the two, FTC-TDF, are now being considered as possible PrEP. TDF and
TDF-FTC have good safety profiles, as well as infrequent side-effects (Grant
et al., 2010; Thigpen et al., 2012; Baeten et al., 2012). Some side-effects in-
clude gastrointestinal discomfort, dizziness, headache, and rash. FTC-TDF
also has occasional skin pigmentation as an adverse effect. Another concern
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is the loss of bone mineral density (Thigpen et al., 2012). Different regimens,
either TDF or FTC or FTC-TDF combinations, and different dosing regimens,
either continuous, intermittent or coitally dependant, are being investigated.
Microbicides are a form of pre-exposure prophylaxis, but generally the two
terms are understood to refer to different routes of administration. Microbi-
cides are administered vaginally and pre-exposure prophylaxis is administered
orally.
2.3.1 Evidence of Efficacy of PrEP
Clinical trials have already been conducted in various settings. A randomized
controlled trial conducted in Ghana, Cameroon and Nigeria could not show
the effectiveness of TDF in preventing HIV infection (Peterson et al., 2007b).
A phase 3 trial involving MSM, referred to as the iPrEx study, has also been
completed recently (Grant et al., 2010). Participants from Peru, Ecuador,
Brazil, the United States, Thailand and South Africa were randomly assigned
to receive either a combination of FTC-TDF (Truvada) or a placebo once daily.
The Truvada showed an efficacy of 44% (95% CI 15–63%). In a sub-analysis of
the iPrEx data, individuals with adherence levels of 90% or more, experienced
an HIV risk reduction of 72.8% (95% CI 40.7–87.5%) if they received Truvada.
Another recent trial, the FEM-PrEP trial, evaluated oral Truvada, with a
sample size of 3900 women (Van Damme et al., 2012). The trial was stopped
early due to a lack of evidence, indicating no conclusive reduction in the rate
of HIV incidence among the trial participants. The lack of efficacy in the
FEM-PrEP trial was likely due to low adherence as less than 40% of the
participants had detectable levels of drugs in their blood. Another clinical
trial among men and women aged 18–39 years in Botwsana investigated the
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impact of FTC-TDF (Thigpen et al., 2012). The overall efficacy of the product
was 62.2% (95% CI 21.5–83.4%) with high levels of acceptability and product
adherence. In another trial, HIV serodiscordant couples in Kenya and Uganda
were randomized in a trial to one of three study groups; receiving either only
TDF, TDF-FTC or a placebo (Baeten et al., 2012). The trial demonstrated
an HIV risk reduction of 67% (95% CI 44–81%) in the TDF arm, and 75%
(95% CI 55–87%) in the TDF-FTC arm. The efficacy was even higher in
subjects who had the study drug detectable in their blood plasma. Results
from the Vaginal and Oral Interventions to Control the Epidemic (VOICE)
trial demonstrated no effectiveness of the oral TDF and FTC-TDF against HIV
acquisition (Marrazzo et al., 2013) and this appeared to be due to low average
levels of adherence. These results are a clear indication of the importance of
adherence.
2.3.2 Acceptability of and Adherence to PrEP
In a study of high risk Ghanaian women aged 18–35 years, the acceptability of
oral TDF was high (Guest et al., 2010). In a cross-sectional study by Heffron
et al. (2012), very high levels of acceptability of PrEP (92.7%) were reported
by the HIV uninfected partners of HIV-positive individuals in Kenya. Most of
the studies focus on self-reported acceptability. There does not seem to be any
data on actual uptake. No relevant studies that focus on the acceptability of
PrEP in adolescents were found, although the Eisingerich et al. (2012) study
found that acceptability was highest in younger adults. This study found
higher acceptability in individuals who had higher consistency of condom use.
Adherence may be related to age as Marrazzo et al. (2013) found drug
concentrations were higher in older women than in younger women. Guest
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et al. (2010) reported that adherence levels were over 80%. Testing for drug
in blood specimens may be a more accurate measure of adherence than pill
counts, and self-reported adherence may be very unreliable (as the VOICE
data show). Adherence levels measured in the different RCTs are in the Table
2.3.
Table 2.3: Adherence levels to PrEP as measured in four randomized control trials.
Trial Reference Pill counts (%) Detectable levels of
drugs (%)
Grant et al. (2010) 95 51
Thigpen et al. (2012) 84.1 81
Baeten et al. (2012) 92.1 82
Van Damme et al. (2012) 86 38
2.3.3 Mathematical Models of Pre-exposure
Prophylaxis
Prior to the effectiveness of PrEP being shown in trials (Grant et al., 2010;
Thigpen et al., 2012; Baeten et al., 2012), modellers assumed a wide range
of values (30–90%) for the efficacy of PrEP to determine its impact on the
HIV epidemic (Abbas et al., 2007; Vissers et al., 2008; Desai et al., 2008;
Paltiel et al., 2009). The deterministic model by Abbas et al. (2007) predicts
that with 90% effective PrEP and 75% coverage of the sexually active target
population, a 74% decrease in HIV incidence can be achieved in 10 years.
With the assumptions of an efficacy of 50% and adherence of 50%, Desai et al.
(2008) predicts that PrEP would avert 8.7% of new infections over a 5 year
period (the population was high risk MSM in New York City).
Some models predict that targeting the most-at-risk population and those
with highest sexual activity, such as 15–35 year old women in South Africa
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(Pretorius et al., 2010), and MSM in the United States (Desai et al., 2008;
Paltiel et al., 2009), would have the greatest impact on HIV incidence and
avert the most HIV infections in the overall population. Very few studies have
considered the effect of targeting PrEP at adolescents/young adults.
A few models have evaluated the possible impact of risk compensation. A
decrease in condom use (Vissers et al., 2008; Van de Vijver et al., 2009; Cremin
et al., 2013) and an increase in risk behaviour (Abbas et al., 2007; Supervie
et al., 2010) could negate the impact of PrEP.
The impact of PrEP, as a method of decreasing susceptibility, in combi-
nation with ART, as a method of reducing infectiousness, has been modelled
(Hallett et al., 2011). This study considered the effect of PrEP and ART in
serodiscordant couples and found that to achieve the most effective impact
on reducing HIV transmission, the HIV uninfected partner should always use
PrEP, or until the HIV infected partner dies, although this may not be the
most cost effective strategy. The model by Cremin et al. (2013) predicts a
huge decline in the level of HIV infection if PrEP is used in combination with
ART and medical male circumcision, but these predictions are only valid at
high coverage levels.
The possible increase in acquired drug resistance with the introduction
of PrEP has become a major concern and has been considered in a number
of modelling studies (Van de Vijver and Coucher, 2010; Supervie et al., 2010;
Baggaley et al., 2011). An increase in risk behaviour could result in an increase
in both acquired and transmitted drug resistance (Supervie et al., 2011). Al-
though all three trials (Grant et al., 2010; Thigpen et al., 2012; Baeten et al.,
2012) have shown very low levels of drug resistance by those participants who
have seroconverted, these results were based on ideal conditions where HIV
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testing was conducted frequently. These same testing conditions may not ap-
ply to the real world. Abbas et al. (2013) predicts that the drug resistance
from ART would far exceed that of PrEP.
2.4 Vaginal Microbicides
Vaginal microbicides are chemical products that can be applied topically to the
vaginal mucosa to reduce the risk of HIV infection, as well as infection by other
STIs. The mucosal epithelium of the vagina does not have a receptor for HIV-
1. For sexual transmission of HIV to occur in females, the virus should thus
pass through the vaginal epithelium to the subepithelial tissue which contains
the target cells, such as the Langerhans cells, T-cells and macrophages (Minces
and McGowan, 2010). Once the virus has passed the epithelial barriers, up-
take of the virus by the dendritic cells occurs and the virus is subsequently
disseminated to the draining lymph nodes, at which point systemic infection
is established (Stone, 2002; Shattock and Moore, 2003).
In order to prevent sexual transmission of HIV, a microbicide should be
capable of the following:
• act as a physical barrier at the vaginal mucosa;
• inactivate the virus while it is still in the vaginal lumen;
• prevent the virus from attaching to and fusing with host cells;
• prevent the virus from replicating if infection of the cells has already
happened (Stone, 2002).
There are various types of vaginal microbicides. Early generations of micro-
bicide products that did not incorporate antiretroviral agents into the mi-
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crobicides were not very successful in preventing HIV infection (Van Damme
et al., 2002; Bax et al., 2002; Peterson et al., 2007a; Van Damme et al., 2008;
Skoler-Karpoff et al., 2008; McCormack et al., 2010; Ramjee et al., 2010).
More recent research has focused on antiretroviral-based vaginal microbicides,
which appear more promising than the previous generations of microbicide
products. The sections that follow focus mainly on these antiretroviral-based
vaginal microbicide products.
2.4.1 Efficacy of Vaginal Microbicides
Effectiveness and safety of 1% tenofovir vaginal gel was assessed by the Centre
for the AIDS Program of Research in South Africa (CAPRISA) 004 trial and
results showed that the gel reduced HIV acquisition by an estimated 39%
overall and by 54% in women with high gel usage (Abdool Karim et al., 2010).
In the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial
5029 women were randomized to use 1 of 3 prevention methods or 2 placebos.
The study was conducted in 3 South African sites, 2 Zimbabwean sites and 1
Ugandan site. One of the 3 prevention methods was a tenofovir-based vaginal
microbicide gel. The results of this trial were not statistically significant as
there were only 15% fewer infections in those women who used the vaginal
microbicide gel when compared with those who used the placebo gel (Marrazzo
et al., 2013).
Innovations in the field of antiretroviral based vaginal microbicides (ARV-
VM) include the development of gel formulations of the nucleotide reverse tran-
scriptase inhibitor (NRTI) tenofovir and non-nucleoside reverse transcriptase
inhibitors (NNRTI) dapivirine and UC781. Phase 2 safety trials for dapivirine
are currently ongoing in Kenya, Malawi, Rwanda, Tanzania and South Africa.
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UC781 gel is currently in phase 1 testing (Ramjee et al., 2010). Viral entry
inhibitors such as chemokine analogues, lectins and monoclonal antibodies are
also being evaluated as potential microbicides (Morris and Lacey, 2010).
2.4.2 Acceptability of and Adherence to Vaginal
Microbicides
There is a high acceptability (>76%)of vaginal microbicides by women as in-
dicated by various phase 1 and 2 trials that have evaluated the acceptability
of the products (Ramjee et al., 2010; Rosen et al., 2008; Altini et al., 2010).
Products are generally liked by both men and women, who report that gel
increases sexual pleasure (Ramjee et al., 2001). Factors that could influence
the acceptability of vaginal microbicides among users are the characteristics
of the products, such as contraceptive or noncontraceptive properties, amount
of lubrication, timing of insertion and the impact on sexual pleasure (Ramjee
et al., 2001). Different product formulations (gel, film, ring) might be pre-
ferred by different women, and offering women a selection of different product
formulations might increase overall acceptability (Nel et al., 2011). A placebo
vaginal ring was found to be highly acceptable among African women in the
acceptability study by Van der Straten et al. (2012).
Adherence by female participants is generally high. Levels of adherence
among women in Zimbabwe to a combination of a gel formulation and a di-
aphragm or a single product gel formulation was measured in a study by
Van der Straten et al. (2008). The study showed that although acceptability
of the products was high, only 56% reported using the gel at every sex act. In
this study, consistent use of the product was significantly associated with older
age. Adherence would be less of an issue with the ring than with any of the
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other product formulations (Van der Straten et al., 2012). Of the participants
in the CAPRISA 004 trial, 38% were highly adherent (>80% gel adherence),
20% had intermediate adherence (50-80% adherence) and 42% had low levels
of adherence (<50% adherence).
Different product formulation options could not only allow for greater ac-
ceptability but also for higher adherence levels which could result in a more
effective microbicide (Nel et al., 2011).
2.4.3 Mathematical Models of Vaginal Microbicides
Several mathematical modelling studies have evaluated the potential population-
level impact of vaginal microbicides. The most important parameter affecting
this impact is the assumed efficacy, with greater reduction in HIV incidence
expected with a product of higher efficacy (Karmon et al., 2003; Smith et al.,
2005; Wilson et al., 2008; Williams et al., 2011). Coverage levels of vaginal
microbicides are also vital. For example, Williams et al. (2011) predicts a
65% reduction in HIV transmission if the coverage levels are high and only
a 53% reduction if coverage is low, in a model based on South African data.
Modelling studies have also shown that adherence is a critical parameter de-
termining population-level impact (Karmon et al., 2003; Wilson et al., 2008;
Williams et al., 2011).
Early models of vaginal microbicides suggest a concern regarding switching
from using condoms to using vaginal microbicides (Foss et al., 2003; Karmon
et al., 2003; Eaton and Kalichman, 2007). The impact of vaginal microbicides
on HIV incidence could be negated should women choose to use the microbi-
cides in place of condoms. Condoms are more effective in reducing the risk of
HIV infection (Pinkerton and Abramson, 1997). There may thus be a trade
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off between uptake and efficacy (Karmon et al., 2003). Risk compensation
is thus a factor to consider, as this could also negate the impact of vaginal
microbicides on HIV incidence (Eaton and Kalichman, 2007).
The development of ARV drug resistance could increase as antiretroviral
microbicides become available for population level use (Morris and Lacey, 2010;
Wilson et al., 2008). Wilson et al. (2008) predict that regular screening during
a trial would mask the true development of ARV resistance and that the ARV
drug resistance would be more prevalent if microbicides were introduced at a
population level with less frequent screening of HIV-negative women.
Combinations of microbicides with other prevention methods have been
modelled. With assumed efficacies of 60% for a microbicide and 60% for male
circumcision, Cox et al. (2011) predicts that the coverage required to achieve
a particular HIV incidence reduction, for a combination of the two prevention
methods is much less than that required for either prevention method alone.
Calibrated to South African data, a model by Long and Stavert (2013) inves-
tigates the impact of a combination of PrEP, MMC and microbicides. The
authors predict that this combination would avert 43.5% of HIV infections.
By adding ART to the combination, the reduction in HIV incidence would be
much greater, 61.9%, over a ten year period.
Although vaginal microbicides are a much needed female-initiated preven-
tion method, the indirect effect on men is also beneficial (Wilson et al., 2008).
A decrease in the prevalence of HIV in females would result in less transmis-
sion, thus affecting the HIV incidence in men.
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2.5 Conclusion
In this Chapter we reviewed the different studies and models that focus on
the sexual behaviour of adolescents. The main concepts included the age of
sexual debut, sexual frequency, partnership formation and dissolution, age-
mixing and the levels of condom use of adolescents. The prevention meth-
ods that we consider are medical male circumcision, pre-exposure prophylaxis
and antiretroviral-based vaginal microbicides, and for each of these prevention
methods we reviewed studies that considered the issues of the acceptability of
and adherence to the prevention methods. Although acceptability of new pre-
vention methods is high, few studies have examined actual uptake, and there
remains much uncertainty regarding the potential for risk compensation. For
evidence of efficacy of the prevention methods, we reviewed the results of the
relevant randomized controlled trials. Although there have been a large num-
ber of mathematical modelling studies that have assessed the effect of these
new prevention strategies, few have assessed the effect of focused provision
of these prevention methods to adolescents. The review of these studies and
models assists us in identifying data sources that are relevant in estimating
the parameters used in our model.
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Mathematical Model
3.1 Method
Stochastic individual-based simulations are typically more complex than de-
terministic compartmental models, but the results are potentially more realis-
tic. Individual-based models can allow for greater heterogeneity in behaviour
and susceptibility to HIV than is typically feasible in a deterministic model.
The stochastic variation is potentially important in the sample size calcula-
tions. The mathematical model developed here is an individual-based stochas-
tic simulation estimating the impact of the various prevention methods on the
heterosexual transmission of HIV among adolescents.
Since the model will be used to simulate a hypothetical randomized con-
trolled trial over a short period, it is sufficient to use a static model. We have
therefore used a static model with the HIV status of partners not enrolled in
the trial being simulated stochastically. Heterosexual HIV transmission is the
only transmission mode considered. The model is used to determine the HIV
incidence in a cohort of adolescents comparing no prevention methods to a sce-
nario in which adolescents are offered multiple HIV prevention methods. This
27
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adolescent population is stratified by age and sex. The prevention methods
under consideration are medical male circumcision, vaginal microbicides and
pre-exposure prophylaxis.
3.2 Modelling the Baseline Characteristics of
each Individual
The population in the model is based on the demography of an adolescent
population living in urban, informal settlements in South Africa. The model is
applied separately to a community in which male circumcision is traditionally
practised and another community in which it is not traditionally practised.
The levels of acceptability and uptake of male circumcision differ in these two
types of communities.
When modelling the baseline characteristics, we first assign sex and age. If
the individual is male, we randomly determine whether or not the individual is
circumcised at baseline. The age of sexual debut is then assigned to determine
whether the individual is sexually experienced at the start of the simulation.
Following this, each individual is randomly assigned a risk level (either low
risk or high risk). Finally, each individual is assigned an HIV status and a
number of partners at baseline.
3.2.1 Sex and Age
The sex of each individual was randomly assigned at the start of the simulation.
We assumed a 1:1 ratio between males and females. For the purpose of the
initial model calibration each individual is randomly assigned an age between
10 and 20 using a uniform distribution. When simulating the actual conditions
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under which the trial is conducted, a narrower age interval (15–18) is used.
3.2.2 Age of Circumcision (males only)
A function that relates the probability of being circumcised to the age of
the individual was used to randomly assign an age at which traditional male
circumcision would be performed (in the absence of MMC). The function was
modelled using a cumulative Weibull distribution. We used the prevalence data
based on Xhosa-speaking males in the traditional male circumcision setting
from a study analysing the national survey of 2002 (Connolly et al., 2008a).
The parameters a and b of the Weibull distribution were estimated based on
this prevalence and a mean age of circumcision of 22.8 years (Rain-Taljaard
et al., 2003). The cumulative density function, given by
C(x, a, b) = 1− e−(xb )a , (3.2.1)
where the shape parameter a was estimated to be 5.9 and the scale parameter
b was estimated to be 24.4, is shown in Figure 3.1 by the dashed line. The
solid line indicates the simulated prevalence of male circumcision, where the
simulated population consisted of 50 000 individuals.
For males in the community where male circumcision is not traditionally
practised, the prevalence of male circumcision is negligible and we thus as-
sumed that none of these males were circumcised at baseline.
3.2.3 Age of Sexual Debut
Each individual’s age of sexual debut was randomly assigned at baseline by
sampling from a Weibull density with a cumulative distribution function,
S(x, cg, dg) = 1− e−(
x
dg
)cg
. (3.2.2)
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Figure 3.1: The prevalence of male circumcision. The dashed line indicates
the function used to relate the probability of being circumcised to the age of circum-
cision and the solid line indicates the simulated prevalence of male circumcision. A
total of 50 000 individuals were simulated, of which 25 333 were males.
The parameters were fitted using data from the NCS survey of 2009 (Johnson
et al., 2010). Figure 3.2 shows the simulated proportion of individuals who
are sexually experienced at the start of the simulation and how they compare
to the survey data. The shape parameter c was estimated to be 8.5 for both
sexes, and the scale parameter d was estimated to be 18 for females and 19 for
males. The age of sexual debut could be lower than estimated in the survey
because when individuals in surveys are interviewed face-to-face, there is the
possibility of creating social desirability bias. This social desirability bias is
likely to be different in males and females (Mensch et al., 2003).
To determine whether or not an individual is sexually active at baseline, we
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compare the individual’s simulated age to the simulated age of sexual debut.
If the individual’s age is less than the age of sexual debut, then the individual
is a virgin at baseline. Otherwise, they are regarded as being sexually active
at the start of the simulation.
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Figure 3.2: Proportions consisting of sexually experienced individuals.
The red lines and dots relate to females and the black lines and dots, males. The total
simulated population size was 50 000. The solid lines are the simulated proportions
of sexually experienced individuals at the start of the simulation. The dashed line
indicates the function that was fitted to the data. The dots are data from the
National HIV Communication Survey of 2009 (Johnson et al., 2010).
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3.2.4 Risk Level
The adolescent population is split into two categories, namely, a high risk
and a low risk category. The high risk category is defined as individuals who
have a propensity for concurrent partners and the low risk category consists
of individuals who are serially monogamous. The risk level is assumed to
depend on the age of sexual debut of the individual based on evidence showing
an association between early sexual debut and high risk behaviour (Pettifor
et al., 2004b; Hallett et al., 2007). We use a logit function to determine the
probability that an individual is in the high risk group, i.e.
logit Rg(s) = pg + qgs, (3.2.3)
where Rg(s) is the percentage of the population of sex g that are high risk
if their age of sexual debut is at age s. The parameters, pg and qg, are set
so that the average proportion of individuals in the high risk group would
be 35% in males and 25% in females. These proportions were chosen to be
consistent with South African survey estimates of the proportions of people
who have ever had concurrent sexual partners (Dunkle et al., 2004; Jewkes
et al., 2002). The values of the parameters p and q were calculated to be 0.745
and -0.08, respectively, for males, and 0.44 and -0.09, respectively, for females.
The negative values for q reflect the negative association between age of sexual
debut, s, and the level of risk behaviour (Eaton et al., 2003; Pettifor et al.,
2007; Wilson et al., 2010). Figure 3.3 gives the probability that an individual
is in the high risk category given their simulated age of sexual debut.
3.2.5 HIV Status
Data used to estimate HIV prevalence at baseline, is from the loveLife survey
of HIV prevalence in South African youth, conducted in 2003 (Pettifor et al.,
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 3. MATHEMATICAL MODEL 33
10 15 20 25 30
10
20
30
40
50
60
70
Age of Sexual Debut
%
 H
ig
h 
Ri
sk
Male
Female 
Figure 3.3: The percentage of high risk individuals. The red lines relate to
females and the black lines, males.
2004a). The data was fitted using a log-normal distribution, similar to that
used by Williams et al. (2000).
For each sex g, we have Hg(x) which is a function that relates the probabil-
ity of being HIV infected to the age of an individual. This is given by equation
(3.2.4).
Hg(x) =
Ng
σg
√
2pi(x− x0)
exp

−
[
ln x−x0
mg
]2
2σg2
 , (3.2.4)
where x is age, with offset x0; mg the mean; σg the scale parameter; and
normalized to Ng. The parameter values for each sex g are in Table 3.1. The
simulated prevalence of HIV in youth compared to the data is shown in Figure
3.4.
The fitted log-normal distribution was adjusted to determine HIV preva-
lence in sexually experienced youth, Lg(x), of sex g and age x and is defined
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by the following equation:
Lg(x) =
Hg(x)
S(x, cg, dg)
=
Ng
σg
√
2pi(x−x0) exp
{
−
[
ln
x−x0
mg
]2
2σg2
}
1− e−( xcg )dg
. (3.2.5)
We then randomly assigned an HIV status to each sexually experienced indi-
vidual based on the estimated probability of HIV infection in equation 3.2.5.
In the case of virgins we assumed the HIV status to be negative.
Table 3.1: The parameter estimates for the baseline characteristics of each individ-
ual’s HIV status used in equation (3.2.4).
Parameters Estimates
(Males)
Estimates
(Females)
N 7 7
x0 1 1
σ 0.3 0.32
m 3.6 3.4
3.2.6 Number of Partners
The rates of partnership formation and dissolution are assumed to depend on
the individual’s risk group r, sex g and the current number of partners. When
assigning the number of current partners to an individual at baseline, we con-
sider the individual’s rate of partner acquisition (λg,r) and rate of partnership
dissolution (µg,r), as well as the extent of their propensity for concurrent part-
nerships (θg,r). In deriving the theoretical distribution of partner numbers in
a cohort of individuals in the steady state equilibrium, we use the same rates,
so that the distribution of partner numbers at baseline depends on sex and
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Figure 3.4: The prevalence of HIV in youth. The red lines and dots relate
to females and the black lines and dots, males. The solid lines are the simulated
HIV prevalence levels at baseline, and the dashed line indicates the fitted log-normal
distribution. The dots are the data points from the loveLife survey of 2003 (Pettifor
et al., 2004a). The simulated population consisted of 50 000 individuals.
risk group. In the multi-state diagram shown in Figure 3.5, Xρ represents the
proportion of the cohort that has ρ current partner(s). Individuals can move
between states as they acquire new partners and as existing partnerships are
dissolved. We assumed that high risk individuals can have a maximum of 2
current partners. The model used for the low risk population is similar to that
of the model used for the high risk population, except that the maximum num-
ber of current partners for the low risk group is assumed to be 1, i.e. setting
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Figure 3.5: A multi-state model of sexual behaviour: used to determine the
number of partners of an individual.
θg,r = 0. This model can be represented by the following system of differential
equations:
dX0
dt
= µg,rX1 − λg,rX0,
dX1
dt
= λg,rX0 + 2µg,rX2 − (µg,r + λg,rθg,r)X1, (3.2.6)
dX2
dt
= λg,rθg,rX1 − 2µg,rX2.
The steady-state distribution of the number of partners was calculated from
the assumed rates of partnership formation λg,r and dissolution µg,r by setting
the above derivatives to zero and the solutions are:
X0 =
2µ2g,r
2µg,r(µg,r + λg,r) + λ2g,rθg,r
, (3.2.7)
X1 =
2µg,rλg,r
2µg,r(µg,r + λg,r) + λ2g,rθg,r
, (3.2.8)
X2 =
λ2g,rθg,r
2µg,r(µg,r + λg,r) + λ2g,rθg,r
. (3.2.9)
Values used for these parameters are in Table 3.2. The parameter estimates
are sourced from a study which considers the dynamics of sexual behaviour in
South Africa in different age groups (Johnson et al., 2009). Their estimates
were based on fitting their model to reported numbers of partners from a
nationally representative survey, as well as to HIV prevalence data. The λ pa-
rameters are those estimated for the 15–19 year age group and the parameters
µ are based on data from Jewkes et al. (2001).
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Table 3.2: Parameter estimates used to determine the steady-state distribution of
the number of partners used in equations (3.2.7)–(3.2.9).
Estimates (Males) Estimates (Females)
Parameters High Risk Low Risk High Risk Low Risk
λ 7.3 1.387 14.6 8.76
θ 0.64 0 0.54 0
µ 2 2 2 2
The number of partners for each individual at baseline was randomly sim-
ulated from a multinomial distribution with parameters determined by this
steady-state distribution of partner numbers (equations (3.2.7)–(3.2.9)).
3.3 Modelling the Partner’s Characteristics
First the sex, then the age and finally the HIV status of the partner(s) of
individuals were assigned.
3.3.1 Partner’s Sex
Since we are only modelling the heterosexual transmission of HIV, the assigned
sex of the partner is the opposite of the individual’s.
3.3.2 Partner’s Age
The simulated age of the partner was based on data from the various studies
previously discussed in section 2.1.4. We assumed an average partner age dif-
ference of 3 years. We assumed that the male’s age is greater than the female’s
age, and that age differences followed a gamma distribution. This distribution
allows for a high level of skewness in the distribution of partner ages whereas
using a Normal distribution would give a completely symmetrical distribution.
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The gamma shape parameter v was set at 1 and the scale parameter w was
set at 3.
Gg(x, v, w) =
1
wvΓ(v)
xv−1e−
x
w . (3.3.1)
We sampled the partner age from this distribution.
3.3.3 Partner’s HIV Status
The HIV status of each partner was randomly assigned in the same manner as
it was assigned for the individuals, i.e. taking into account the assumed log-
normal relationship between HIV prevalence and age, and adjusted for sexual
experience.
3.4 Modelling Movements Between States
The method used to model the movements between the states in adolescents
is based on a stochastic simulation technique by Hansen (2000). For each indi-
vidual in the modelled population, we determine the time to their next possible
event and then which event it could be. Events include getting circumcised
(in the case of uncircumcised males), becoming sexually active, forming a new
partnership, dissolving a current partnership and becoming infected with HIV.
The primary outcome in which we are interested is new HIV infections, and
events occurring after HIV is acquired, such as the HIV disease progression or
AIDS mortality, are therefore not modelled. Although we model HIV preva-
lence, we do not simulate AIDS mortality or non-AIDS mortality as both
mortality rates are very low during adolescence (Zaba et al., 2007). A multi-
state model based on the characteristics of the model population is used to
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determine the possible events that could occur in an individual, as well as the
time to the event. Figure 3.6 shows the multi-state model for an individual
in the high risk group. Uncircumcised males are represented in the top half
(Figure 3.6) and both females and circumcised males are represented in the
lower half (Figure 3.6). Individuals can either be virgins, or sexually active
with 0, 1 or 2 partners. In the multi-state model for individuals in the low
risk group, the transition rate to the life-state "2 Partners" is set to zero since
by definition individuals in the low risk group do not engage in concurrent
partnerships.
Uncircumcised males, shown in the top half of Figure 3.6 could get circum-
cised when they are in any of the states. If they do get circumcised, they move
to the corresponding state shown in the lower half of Figure 3.6. Individuals in
the "virgin" state move to the "1 Partner" state on becoming sexually active.
Once an individual is sexually active with one partner, there are 4 possible
events that could occur:
• get circumcised (in the case of uncircumcised males);
• $1: form a new partnership;
• $2: dissolve a partnership; or
• $3: become infected with HIV, if their partner is HIV infected.
The time to circumcision is determined by subtracting the individual’s current
age from their age at circumcision (determined when simulating the baseline
characteristics). Similarly, the time to becoming sexually active is determined
by subtracting their current age from their age of sexual debut. The duration
to male circumcision could change when we simulate the prevention methods
since the prevention package could result in an increase in uptake of medical
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Figure 3.6: Multi-state model of sexual behaviour and HIV transmission:
(a) Uncircumcised males; (b) Females and circumcised males. The dashed arrows
from life-states in (a) to life-states in (b) indicate male circumcision.
male circumcision. To determine the time to any of the other three remaining
possible events for individual i, we set
Ti(t) = 1− exp(−
3∑
q=1
ϑi(q)t), (3.4.1)
where Ti(t) is the probability an event occurs before time t, and ϑi(q) is the
rate at which event q occurs in individual i. The rates are defined as follows:
• when q = 1, then ϑi(1) is the rate of partnership formation;
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• when q = 2, then ϑi(2) is the rate of partnership dissolution; and
• when q = 3, then ϑi(3) is the rate of HIV infection, if their partner is
HIV infected.
Using equation 3.4.1 and equating Ti(t) to a random number r1, generated
from the uniform (0, 1) distribution, we determine the time to the next event;
i.e.
ti =
− log(1− r1)∑3
q=1 ϑi(q)
.
To determine which event occurs, we calculate the probability of each event,
P ($k).
P ($k) =
ϑi(k)∑3
q=1 ϑi(q)
,
for k = 1, 2, 3. We randomly determine the event by generating a random
number r2 from the uniform (0, 1) distribution, i.e.
• if r2 < P ($1) then the event is $1, or
• if P ($1) ≤ r2 < (P ($1) + P ($2)) then the event is $2, or
• if r2 ≥ (P ($1) + P ($2)) then the event is $3.
All the rates ϑi(q) are annual rates, and depend on the individual’s sex g, risk
level r and current number of partners ρ. The values of ϑi(1) and ϑi(2) are
identical to the parameter values for λg,r (the rates of partnership formation)
and µg,r (the rates of partnership dissolution), respectively, as described in
section 3.2.6 in Table 3.2.
3.4.1 The Rate of HIV Infection
The rate of HIV infection ϑi(3) for individual i depends on the following pa-
rameters.
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3.4.1.1 The annual rate of sexual contact n:
Estimates from Pettifor et al. (2004a) and Kelly (2000) were used to determine
an estimate for n (described in the section 2.1.2). We assumed n to be 3 acts
per 4-week period, i.e. 39 per annum.
3.4.1.2 The probability of condom usage γ:
The NCS of 2009, reports the frequency of condom use at last sex for ages 16–
19 as 75% for males and 63% for females, and for ages 20–24 as 68% for males
and 49% for females (Johnson et al., 2010). For our simulation we assumed
rates of 60% for both sexes, lower than the reported rates to make allowance
for probable over-reporting of condom use.
3.4.1.3 The efficacy of a condom in preventing HIV transmission
E:
We assumed an efficacy of 90% (Pinkerton and Abramson, 1997).
3.4.1.4 The probability of HIV transmission per act of
unprotected sex with an HIV infected partner βi:
We assumed a value of 0.0128, (Baeten et al., 2005), for the female-to-male
HIV transmission probability for all uncircumcised males in the simulation.
For the male-to-female HIV transmission probability, an estimate of 0.04 was
assumed (Pettifor et al., 2007).
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3.4.1.5 Efficacy of male circumcision in preventing HIV
transmission φi:
For circumcised males, an efficacy of 60% was assumed (Mills et al., 2008).
For females and uncircumcised males, φi = 0.
The annual rate at which an individual becomes infected if their partner is
HIV-positive is given by the equation:
ϑi(3) = nβi(1− γE)(1− φi). (3.4.2)
In the event that a high risk individual has two HIV-positive partners, the rate
of becoming HIV infected is doubled. We are not considering any variation in
the annual rate of HIV transmission per sex act and thus the stages of HIV
that impacts the rate of HIV transmission are not considered in our model.
Once an event, $k, is determined, the appropriate adjustments to the indi-
vidual’s characteristics are made. We simulate the sequence of events occurring
in each individual, over a fixed period, and then aggregate the results for all
individuals to calculate HIV incidence and HIV prevalence at the end of the
period.
3.5 Model Estimates of HIV Incidence and
HIV Prevalence in the Baseline Scenario
HIV incidence in the cohort of adolescents is the main output of the simulation.
We simulated a population of 50000 individuals over a 4 year period. For
the purpose of calibration, we simulated a cohort that was initially aged 10–
24 years. We simulated individuals from urban informal settlements, where
the HIV prevalence is relatively high. The simulated HIV incidence and age-
specific incidence was then compared to previously-published estimates of HIV
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incidence in South African youth (Johnson et al., 2012; Rehle et al., 2010;
Shisana et al., 2009).
Figure 3.7 shows the simulated change in age-specific HIV prevalence over
the four year term of the projection for both males and females. If HIV in-
cidence rates were stable over time, we would expect no change in prevalence
over the four year term of the simulation. The HIV prevalence comparisons
for females aged 14–19 years illustrates a decline in prevalence. For females
aged 20–24 years, there is an increase in the simulated HIV prevalence. This
could be due to the fact that the model does not allow for marriage/long-term
relationships. Females who do enter long-term relationships will generally be
at a lower risk of HIV, and they will be a substantial proportion of 20–24 year
olds but a small fraction of 15–19 year olds (Bongaarts, 2007). The model
also does not account for the age-related changes in cervical ectopy which
is more prevalent in younger females than older females (Myer et al., 2006).
Cervical ectopy is associated with greater HIV susceptibility (Moscicki et al.,
2001; Moss et al., 1991), and the assumption that the transmission probability
in 20–24 year old females is the same as that in the 15–19 year old females
may therefore be leading to exaggerated estimates of HIV prevalence in 20–24
year old females. The male age-specific HIV prevalence levels do not change
substantially over the four year projection term.
The age-specific HIV incidence for the simulation was calculated using the
following formula:
Incidence at age x =
Hx
Px
,
where Hx is the number of new HIV infections at age x and Px is the number
of HIV negative person-years for age x. We calculated the HIV incidence for
age groups 15–19, 15–24 and 20–24 year olds, which we used to compare to
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Figure 3.7: Simulated HIV prevalence comparisons for males (left) and
females (right): at baseline and at the end of the trial.
other model estimates (Rehle et al., 2010; Johnson et al., 2012).
Figure 3.8 shows the comparison between the simulated HIV incidence and
the HIV incidence rates estimated by the STI-HIV model and the ASSA2003
model (Johnson et al., 2012) at the start of 2008. The simulated incidence for
females in the 15–19 year age group is roughly consistent with the STI-HIV
model but slightly lower than the ASSA2003 model. The simulated incidence
for females in the 20–24 year age group is much higher than that of the other
2 models. This again could be due to the model not allowing for the change
in the transmission probability at older ages or entry into long term relation-
ships. Although the model estimates are likely to be unrealistic for women
aged 20–24, this is not a major concern as we are primarily interested in HIV
incidence in adolescents (aged < 20). For males in the 15–19 year age group,
the simulated incidence is slightly higher than that of the other 2 models.
Both the STI-HIV and ASSA2003 models consistently underestimate the HIV
prevalence for this age group (Johnson et al., 2012), thereby underestimating
the incidence. In the 20–24 year age group, the simulated male incidence is
consistent with both the STI-HIV and ASSA2003 models. However, the model
estimates for this group do not reflect the overestimated incidence as that of
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their female counterparts. The transmission probability for males remains the
same because males are less likely to enter in long term relationships at young
ages, unlike their female counterparts, and the cervical ectopy does not apply
to men. Since the model is static, not dynamic, the overstated HIV prevalence
in women aged 20–24 has no effect on the model estimates of male prevalence
in the 20–24 age group.
Figure 3.8: HIV incidence comparisons: for males and females between the
STI-HIV Model (Johnson et al., 2012), ASSA2003 Model (Johnson et al., 2012) and
the simulated incidence over a four year period for the age groups 15–19 and 20–24.
Figure 3.9 illustrates the comparison between the simulated incidence and
the incidence estimated by Rehle et al. (2010) for both males and females in the
age group 15–24 years. Rehle et al. (2010) uses data from the HSRC national
household surveys of 2002, 2005 and 2008 to determine the HIV incidence over
the periods between the surveys. For males, our model estimate of incidence
is higher but not much different from the HSRC estimates and for females, the
simulated incidence lies in between the HSRC estimates for the 2002–2005 and
2005–2008 periods (Rehle et al., 2010).
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Figure 3.9: HIV incidence comparisons: for males and females between the
HSRC 2002–2005 (Rehle et al., 2010) and the HSRC 2005–2008 (Rehle et al., 2010)
and the simulated incidence over a four year period for the age group 15–24.
3.6 Conclusion
In this Chapter we developed an individual-based stochastic simulation that
we use to estimate the HIV incidence among a cohort of adolescents, with no
prevention methods. We used a multi-state model of sexual behaviour and
HIV transmission, based on the characteristics of the modelled population of
adolescents, to model the movements between the different states. Since the
focus is HIV incidence, no events after HIV infection, such as HIV disease pro-
gression or AIDS mortality, is considered. The model is calibrated to South
African data. The estimates of HIV incidence and HIV prevalence of this base-
case model is roughly consistent with other South African estimates of HIV
incidence. In the next Chapter, we extend this model to simulate a hypothet-
ical individual-based randomized controlled trial where the individuals in the
intervention arm are offered a choice of different prevention methods.
Stellenbosch University http://scholar.sun.ac.za
Chapter 4
Clinical Trial Simulation
By extending the base-case model, we now simulate a hypothetical individual-
based randomized controlled trial. A sample population is randomly assigned
to either the control arm or the intervention arm of the trial. We use the
model to determine the impact of various intervention packages on HIV inci-
dence over a hypothetical trial duration of 3 years. We then compare different
prevention packages, and by determining the relative risk of HIV incidence
for each package, we select the best package to offer as an HIV intervention
strategy.
4.1 The Baseline Characteristics
Using the model developed in Chapter 3, we simulated a sample of 2000 in-
dividuals. The sex, age of sexual debut, risk level and number of partners
were simulated in the same manner as described in section 3.2. The remaining
baseline characteristics were simulated as follows:
• Age: For the purpose of the trial, we assumed adolescents would only
be recruited in the age range of 15–18 years.
48
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• Male circumcision: Taking into account that trial participants would
be from different sites in which different cultural norms apply, we first se-
lected the circumcision setting/background for each male. Fifty percent
of the males were assumed to be from a setting that practises traditional
male circumcision, where the individual is then assigned an age of tra-
ditional circumcision (in the same way as described in section 3.2.2),
and the remaining 50% are from a setting where male circumcision is
not practised traditionally and these males were assigned a status of not
circumcised at baseline. Both the control arm and the intervention arm
then consists of males that are from both settings. Males in the interven-
tion arm were offered MMC at baseline. Uptake of MMC was assumed
to be lower for males from the traditional male circumcision setting than
from the setting in which male circumcision is not traditionally practised
(Scott et al., 2005; Mark et al., 2012; Gray et al., 2012).
• HIV status: All individuals were assigned a negative status, since the
trial would only recruit adolescents who are initially HIV negative.
The characteristics of the partners were simulated using the method described
in section 3.3, first assigning a sex, then an age, followed by an HIV status.
Once all individuals are created, we randomly assigned half the sample to a
control arm. The remaining half was assigned to the intervention arm. The
intervention arm was then offered a selection of prevention methods.
4.2 The Prevention Methods
Individuals in the intervention arm of the trial are offered prevention methods
from a prevention package. The options for males included:
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• medical male circumcision(MMC) - for uncircumcised males and
• PrEP.
For females, the options were either
• Vaginal microbicide gel formulation (VM-gel),
• Vaginal microbicide ring formulation (VM-ring), or
• PrEP.
When accounting for the impact of the prevention methods, we considered
• the acceptability of the prevention methods,
• the adherence to the products, and
• the efficacy of the different prevention methods.
Prevention method choices and levels of adherence were randomly generated
for each individual. The simulation of the choice by an individual is described
in the section 4.2.2.
4.2.1 Condom Use Consistency
Condoms are considered to be a highly effective method of HIV prevention. In
the previous model we assumed no heterogeneity in condom use with an overall
rate of condom use of 60% (subsubsection 3.4.1.2). However, consistency of
condom use varies from individual to individual. We adapted the model to
allow for the heterogeneity in condom use because there may be important
interactions between consistency of condom use and uptake of other prevention
methods. According to the loveLife survey of 2003, 33% of youth reported
always using condoms, 31% reported never using condoms, and the overall
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proportion who used condoms at last sex was 52% (Pettifor et al., 2004a).
Taking this variation in condom use into account, each individual was assigned
their own level of condom use. We referred to this as a condom use score Scon
which was assumed to beta-distributed. By simulating a random number z1
from the uniform U(0,1) distribution, we determined the pth quantile of the
beta distribution using the inverse of the cumulative distribution function.
F(p, w, y) =
1
B(w, y)
∫ p
0
tw−1(1− t)y−1dt, (4.2.1)
where B(w, y) is the beta function. B(w, y) is defined in terms of the gamma
function Γ(·), i.e.
B(w, y) =
Γ(w)Γ(y)
Γ(w + y)
, (4.2.2)
where the shape parameters, w and y, are defined in terms of the mean ηcon
and variance κcon. The first shape parameter w =
(
1−ηcon
κ2con
− 1
ηcon
)
η2con and the
second shape parameter y = w
(
1
ηcon
− 1
)
.
The mean ηcon of the beta distribution is the average rate of condom use.
We assumed an average rate of condom use of 60%, the same as for the model
in section 3.4.1.2. The variance parameter κcon was set at 0.15, which leads to
20% of youth using condoms in less than 10% of sex acts and 39% of youth
using condoms in more than 90% of sex acts (roughly consistent with the
observed heterogeneity in consistency of condom use).
4.2.2 Modelling the Acceptability and Uptake of the
Prevention Methods
In our model we assume a positive correlation between condom use and the
acceptability of other prevention methods. This implies that if an individual
has a high rate of condom use, they are more likely to accept other forms of
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prevention methods, whereas individuals who do not use condoms would be
less interested in other prevention methods.
The assumption of positive correlation based on data showing a positive
association between consistent condom use and PrEP acceptability (Eisin-
gerich et al., 2012). When modelling the acceptability of a prevention method,
each individual was assigned their own level of acceptability for each preven-
tion method. Acceptability scores were assumed to follow a beta distribution.
Using a new random number z2 and assuming a positive correlation between
condom use and acceptability of other prevention methods, we used the inverse
cumulative distribution function of the beta distribution to randomly assign
an acceptability score SIacc for each prevention method I to each individual.
The probability argument z2 used to determine the pth quantile of SIacc, was
determined as follows
z2 = b1z1 + (1− b1)q1, (4.2.3)
where q1 is a random number from the uniform U(0,1) distribution and b1 lies
between (0, 1). When b1 = 0 there is no correlation between acceptability and
consistency of condom use, and when b1 = 1 there is perfect correlation. For
our simulation we assumed b1 = 0.5. z1 is the same random number used
to determine the condom use score Scon. For each prevention method I we
assumed different mean levels of acceptability ηIacc and standard deviations of
acceptability scores κIacc.
• MMC
For males from a setting that practises traditional circumcision, we as-
sumed a mean level of acceptability of MMC of 0.10 (Mark et al., 2012).
For males from a setting that does not practise traditional circumcision,
the mean level of acceptability assumed was 0.8 (Scott et al., 2005; Lis-
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souba et al., 2011; Gray et al., 2012).
• PrEP
The mean level of acceptability of PrEP for both males and females was
assumed to be 0.70 (Eisingerich et al., 2012).
• VM-gel formulation
We assumed a 0.70 mean level of acceptability for this formulation (Ram-
jee et al., 2010; Altini et al., 2010; Rosen et al., 2008).
• VM-ring formulation
A mean level of acceptability of 0.90 was assumed for the ring formulation
of vaginal microbicide (Van der Straten et al., 2012).
The product formulation of vaginal microbicides plays a vital role in acceptabil-
ity of the product. It has been shown that a product, like the gel formulation,
requiring frequent application is less acceptable than one that has a once off
application, like ring formulation (Montgomery et al., 2012). Thus the mean
level of acceptability for the VM-ring formulation was assumed to be higher
than that of the VM-gel formulation.
The assumed variance κIacc used in the calculations of SIacc was determined
as follows:
if ηIacc ≥ 0.5, then κIacc =
(
1
2
(1− ηIacc)
)2
;
if ηIacc < 0.5, then κ
I
acc =
(
1
2
ηIacc
)2
.
These variance assumptions have been set arbitrarily, as we lack the detailed
data required to determine the variation in acceptability.
For females, once an acceptability score for each prevention method SIacc
was assigned, we then determined the uptake of a prevention method. Females
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were not allowed to use more than one prevention method simultaneously (oth-
erwise there would be an overdosing of tenofovir/truvada). We generated a
random number r1 from the uniform U(0,1) distribution and also calculated the
individual’s highest level of acceptability score max(SIacc). If max(SIacc)≥ r1,
then the female was allocated the prevention method with the highest accept-
ability score, otherwise no prevention method was allocated. Since males may
have the option of selecting both MMC and PrEP, we first simulated whether
or not they selected MMC, then we simulated whether they selected PrEP or
not. Again, the allocation of MMC was determined by comparing the SMMCacc
to a random number r2 generated from the uniform U(0,1) distribution. If
SMMCacc ≥ r2 then the male was allocated MMC. The determination of whether
or not the male accepted PrEP was simulated in the same manner.
4.2.3 Modelling of Adherence to the Prevention
Methods
Once an individual has selected a prevention method, they are then assigned
their own level of adherence to this prevention method. This level of adher-
ence is represented by an adherence score SIadh, which is assumed to be beta-
distributed. We assume a positive correlation between the level of acceptability
of a prevention method and the level of adherence to the prevention method,
based on data showing the relationship between microbicide acceptability and
adherence (Van der Straten et al., 2008). We use the inverse cumulative dis-
tribution function of the beta distribution to determine the pth quantile, SIadh.
The random number z3 used to sample from this beta distribution is:
z3 = b2z2 + (1− b2)q2,
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where q2 is a random number from the uniform U(0,1) distribution. Again we
assumed b2 = 0.5. Based on the specified studies the assumed mean levels of
adherence to the prevention methods are:
• PrEP - 70% (Thigpen et al., 2012; Baeten et al., 2012)
• VM-gel formulation - 60%. Although Van der Straten et al. (2008) and
Abdool Karim et al. (2010) measured adherence levels of 80% and 72%,
respectively, the adherence levels of the VOICE trial suggest much lower
adherence levels (Microbicide Trials Network, 2011).
• VM-ring formulation - 90%. Montgomery et al. (2012) measures adher-
ence levels of above 90% for a vaginal ring.
Product application affects the level of adherence to products. Since the VM-
ring formulation requires less frequent application, the level of adherence to
a ring formulation of the vaginal microbicide would probably be higher than
that of a gel formulation. If no prevention method was assigned as a choice,
then SIadh = 0. The assumed variance, κIadh, used in the calculations of SIadh is
determined as follows:
if ηIadh ≥ 0.5, then κIadh =
(
1
2
(1− ηIadh)
)2
;
if ηIadh < 0.5, then κ
I
adh =
(
1
2
ηIadh
)2
.
The variance assumption is arbitrary because we do not have detailed data on
the extent of the heterogeneity in adherence.
4.2.4 Efficacy of the Prevention Methods
Based on randomized trials, we assumed the following efficacy levels EI for
each prevention method I, if adherence is perfect:
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• Male circumcision - 0.60 (Auvert et al., 2005);
• PrEP - 0.85 (Grant et al., 2010; Thigpen et al., 2012; Baeten et al., 2012);
• VM-gel formulation - 0.65 (Abdool Karim et al., 2010);
• VM-ring formulation - 0.65. This is assumed to be the same as that for
the gel since there have not been any trials that indicate the efficacy of
the ring formulation of vaginal microbicides.
The levels of efficacy assumed for the last three prevention methods are based
on an adherence level of 100%.
Table 4.1 summarises the estimates for the mean levels of acceptability of
and adherence to the prevention methods, as well as the efficacy of the various
prevention methods when we assume perfect adherence.
Table 4.1: Summary of parameter estimates used to determine each individual’s
level of acceptability and adherence, and the efficacy of the prevention methods when
assuming complete adherence.
Intervention Mean Acceptability Mean Adherence Efficacy
Male Female Male Female Male Female
MMC Trad: 0.1 NA NA NA 0.6 NA
Medical: 0.8
PrEP 0.7 0.7 0.7 0.7 0.85 0.85
VM-Gel NA 0.7 NA 0.6 NA 0.65
VM-Ring NA 0.9 NA 0.9 NA 0.65
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4.3 Modelling the HIV Incidence in Trial
Participants
4.3.1 Intervention Arm of Trial
At the start of the trial, using the acceptability score for MMC, SMMCacc , as-
signed to uncircumcised males, we randomly assigned whether or not the in-
dividual selected this prevention method as an option. For those who opted
for MMC, we updated their circumcision status to circumcised. The uncir-
cumcised males, who have been assigned an age of traditional circumcision,
could get circumcised during the course of the trial through traditional cer-
emonies. The method used to model individual i’s movements between the
different states is the same as described in section 3.4, but the annual rate
of HIV infection ϑi(3), if their partner is HIV infected, is now calculated as
follows:
ϑi(3) = nβi(1− EScon,i)(1− φi)(1− SIadh,iEIi ), (4.3.1)
where n is the annual rate of sexual contact, E is the efficacy of a condom
in preventing HIV transmission, βi is the probability of HIV transmission per
act of unprotected sex with an HIV infected partner, and φi is the efficacy
of male circumcision in preventing HIV transmission, the same as in section
3.4. I represents the antiretroviral prevention method chosen by individual i
(in the event that no antiretroviral prevention method is chosen, SIadh,i is 0).
The condom score Scon,i, the adherence score SIadh,i, and the efficacy of the
prevention method EI , are determined for each individual as explained before.
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4.3.2 Comparison with the Control Arm
Modelling of movements between states in the control arm of the trial is the
same as in section 3.4. The only change is that the probability of condom
usage γ, from equation (3.4.2), is replaced with the individual condom score,
Scon,i. Thus the annual rate of HIV infection ϑi(3), if their partner is HIV
infected, is now
ϑi(3) = nβi(1− EScon,i)(1− φi). (4.3.2)
At the end of the 3 year time period, we determine the HIV incidence, I, in
both arms of the trial. Using these incidence values, we determine the relative
risk of HIV infection RR as follows:
RR =
Iintervention
Icontrol
.
The trial is simulated 1000 times. The 95% confidence intervals around the
mean relative risk of HIV infection are reported.
4.4 Results
In this section we focus on the impact of different intervention packages on
HIV incidence and we consider different trial sample sizes. All the results are
based on the assumption that there is positive correlation between the assumed
levels of condom use and the acceptability of other prevention methods. As a
sensitivity analysis, we illustrate the impact of a package when we assume a
negative correlation between condom use and acceptability of other prevention
methods.
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4.4.1 Intervention Packages
In order to determine the mean relative risk of HIV infection, we ran 1000
trial simulations for a sample size of 2000 individuals, 1000 individuals in each
arm, for each of the packages described in Table 4.2.
Table 4.2: The different prevention methods included in
the various packages used in the model.
Package Prevention Methods
1 MMC, PrEP, VM-gel and VM-ring
2 MMC, VM-gel and VM-ring
3 MMC, PrEP and VM-ring
4 MMC, PrEP and VM-gel
For the simulation of package 1, out of a mean total of 486 males in the
intervention arm, 64 (13%) chose only MMC , 213 (43%) chose only PrEP, 139
(28%) chose both prevention methods and 70 (14%) chose neither prevention
method. For the remaining 514 females, 465 (90%) chose the VM-ring option,
1 (<1%) chose the VM-gel option, 1 chose PrEP (<1%) and 39 (8%) did not
opt for a prevention method. The model estimate for the mean HIV incidence
rate (Figure 4.1) in the intervention arm is 0.92 per 100 person-years (95% CI
0.91–0.93 per 100 person-years), and the estimate in the control arm is 1.73 per
100 person-years (95% CI 1.71–1.75 per 100 person-years). The mean relative
risk of HIV infection (Figure 4.2) is 0.54 (95% CI 0.53–0.55).
The impact of package 1 is greater in males than in females, with the
mean relative risk of HIV infection for males at 0.51, lower than that for the
females, 0.57 (Figure 4.2). The main reason for this is that males can choose
both MMC and PrEP prevention methods, whereas females can choose only
1 of the 3 applicable options. Females were more likely to choose the vaginal
ring over PrEP, because the assumed mean acceptability level for the vaginal
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Figure 4.1: HIV incidence rate: for males, females and in total. The HIV
incidence rates are given per 100 person-years and were determined for 1000 trial
simulations for a sample size of 2000 individuals offered package 1, over a 3 year trial
period.
ring (90%) was much higher than that for PrEP and the vaginal gel (70%).
Having the option of both MMC and PrEP, most males opted to use PrEP,
regardless of whether they chose MMC or not. Although the stated efficacy
assumptions are based on an assumption of perfect adherence, we allow for
imperfect adherence in the model which reduces the actual effectiveness of the
prevention method.
4.4.1.1 Various Intervention Packages
The mean relative risk of HIV infection with 95% confidence intervals was
calculated for each of the four packages for the sample in total, as well as for
each sex. Figure 4.2 shows the comparisons for the mean relative risk of HIV
infection between the different packages.
For males, package 1, 3 and 4 have the same components, and thus the
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 4. CLINICAL TRIAL SIMULATION 61
Figure 4.2: Comparison of relative risk estimates for different intervention
packages. The mean relative risk of HIV infection was determined for 1000 trial
simulations for a sample size of 2000 individuals over a 3 year trial period.
results for the relative risk of HIV infection are similar (0.51). For package
2, males only have the option of MMC. This results in an estimated relative
risk of HIV infection of 0.80, much higher than that estimated for the other
packages. With the high levels of acceptability and overall efficacy of PrEP,
we find that the exclusion of PrEP from a prevention package increases the
mean relative risk of HIV infection although this exclusion only has a material
impact on HIV incidence in men.
For females, the mean relative risk of HIV infection is almost identical
for packages 1, 2 and 3. Uptake estimates of the VM-ring option for these
packages are similar to that of package 1 (≈90%) and this results in similar
estimates for the relative risk of HIV infection. When we compare the impact
of packages 1, 2 and 3, where more than 90% of the women chose the VM-ring
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option that has an assumed efficacy of 0.65 with a mean level of adherence of
90%, to the impact of package 4, where the assumed levels of efficacy of PrEP
(0.85) and VM-gel (0.65) are different with both having lower mean levels of
adherence (70% for PrEP and 60% for the VM-gel), we find that estimates of
HIV incidence are much lower for the first 3 packages. Thus, as with package
4, our model suggests that the exclusion of the ring formulation results in a
higher mean relative risk (0.73) for females.
We also simulated the impact of the individual prevention methods. Figure
4.3 illustrates the impact of the prevention methods for males (upper panel)
and females (lower panel). For the males, the combination of the prevention
methods has a greater impact on HIV incidence. The VM-ring, as a single
intervention for the females, has the lowest mean relative risk of HIV infection,
with PrEP having the next lowest. The aggregate levels of effectiveness depend
on acceptability, adherence and efficacy. VM-ring, having the highest mean
level of adherence, would result in a much higher level of efficacy as compared
to the other prevention methods. The higher the assumed efficacy, the lower
the mean relative risk of HIV infection.
4.4.2 Sensitivity Analyses
We conducted a sensitivity analyses around the impact of different sample
sizes, as well as the correlation between levels of condom use and the levels of
acceptability of other prevention methods.
4.4.2.1 Sample Size Consideration
Sample size plays a vital role in determining statistical significance and it is
important that the sample size chosen is sufficient to ensure that the trial is
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Figure 4.3: Comparisons of the mean relative risk estimates for individual
prevention methods: for males (above) and females (below). The mean relative
risk of HIV infection was determined for 1000 trial simulations for a sample size of
2000 individuals over a 3 year trial period.
adequately powered to detect the expected effect on HIV incidence. We ran
another 1000 trial simulations with a sample size of 500 individuals in each
simulation to illustrate the importance of sample size. Figure 4.4 compares
the mean relative risk of HIV infection for samples of 500 and 2000 individuals
who were offered intervention package 1. The mean relative risk of HIV infec-
tion is reported together with the 2.5 and 97.5 percentiles of the distribution
of relative risk values generated from the 1000 simulations (95% C.I.). The
relative risk of HIV infection for the smaller sample is 0.58 (95% CI 0.16–1.29)
and for the larger sample is 0.54 (95% CI 0.33–0.87). The confidence interval is
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therefore substantially narrower when the sample size is larger. With sample
size 2000, we would expect the relative risk of HIV infection to be below 1 in
at least 97.5% of trials, though it would not necessarily be significantly below
1 in all 97.5% of the simulations.
We calculated the power to detect a statistically significant difference for
each sample size by determining the proportion of simulations in which the
upper 95% confidence interval limit of the relative risk was lower than 1. For
a trial of sample size 500 we estimated only 23.1% power, whereas for a trial
of sample size 2000 we estimated a power of 78.1%. This model output is
verified using the R statistical software package. With an input of 78.1%
power, an incidence rate of 1.73 per 100 person-years in the control arm, and a
relative risk of 0.54, and using a two-sided test with an alpha level of 0.05, the
programme estimates a sample size requirement of ∼966 individuals per trial
arm or about 1932 in total (similar to the sample size of 2000 in our model).
Using the sample size estimation function in R, we calculated that a sample
size requirement of ∼1013 in each arm of a trial would achieve 80% power,
with a two-sided alpha level of 0.05, to detect a relative risk of HIV infection
of 54%, with a mean incidence rate of 1.73 per 100 person-years in the control
arm.
4.4.2.2 Correlation Between Condom Use and Acceptability of
Other Prevention Methods
In all of the previous simulations we assumed a positive correlation between
the level of condom use and the level of acceptability of prevention methods.
We now consider the impact of the packages on HIV incidence when we assume
a negative correlation between the level of condom use and the acceptability
of the other prevention methods, and then we compare the results to that of
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Figure 4.4: Comparisons of relative risk estimates for different sample
sizes: for males, females and in total. The RRs are determined for 1000 trial
simulations for each of the sample sizes of 500 and 2000 individuals over a 3 year
trial period. The confidence intervals are calculated from the 2.5 and 97.5 percentiles
of the distributions of simulated RR values.
our previous simulations. A negative correlation can be interpreted as follows:
individuals who have a high rate of condom use do not see the need for any
other prevention methods and are thus less likely to accept any other preven-
tion method, and individuals who have a low rate of condom use would find
other prevention methods more appealing and thus have a higher chance of
accepting other prevention methods. To allow for this negative correlation we
modify equation 4.2.3 as follows
z2 = b1(1− z1) + (1− b1)q1, (4.4.1)
and again we assume b1 to be 0.5. Each individual is again assigned an accept-
ability score, SIacc,i for prevention method I based on this value for z2, and the
rest of the model remains the same. Figure 4.5 illustrates how this negative
correlation affects the relative risk of HIV infection for intervention package 1.
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 4. CLINICAL TRIAL SIMULATION 66
Figure 4.5: Comparison of the relative risk estimates when assuming
negative correlation and when assuming positive correlation, between the
level of condom use and the level of acceptability of other prevention
methods. In each, we simulated 1000 trial simulations for a sample size of 2000
individuals over a 3 year trial period for a full package.
The relative risk of infection when assuming a negative correlation between
condom use and the acceptability of a prevention method is 0.51 (95% CI 0.50–
0.52). This is lower than the relative risk of HIV infection when assuming a
positive correlation, 0.54 (95% CI 0.53–0.55). The effect of negative correlation
in males is greater than that in females. The prevention methods for the males
are not mutually exclusive, so there is a compounding of the correlation effect.
Also, when assuming a positive correlation, the proportion of males that are
not selecting any method in package 1 is much higher than that of the females.
We simulated the impact of a single prevention method, PrEP, assuming
first a positive then a negative correlation between the level of condom use and
the acceptability of PrEP. The relative risk of HIV infection is 0.66 (95% CI
0.65–0.67) when assuming a positive correlation and 0.60 (95% CI 0.59–0.61)
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when assuming a negative correlation. Figure 4.6 illustrates this comparison.
For PrEP, we find that the differences between males and females are similar.
Figure 4.6: Comparison of the relative risk estimates when assuming
negative correlation and when assuming positive correlation, between the
level of condom use and the level of acceptability of PrEP. In each, we
simulated 1000 trial simulations for a sample size of 2000 individuals over a 3 year
trial period for the single prevention method, PrEP.
The assumption of negative correlation gives a higher impact because in-
dividuals who have a low level of condom use are now more likely to use other
prevention methods thereby decreasing their relative risk of HIV infection and
individuals with high levels of condom use are already protected due to the high
levels of condom efficacy. Although individuals with a high level of condom use
are opting for additional protection by using another prevention method when
we assume positive correlation, the interaction between the combination of the
prevention methods are redundant. By not opting for additional protection,
individuals with a low level of condom use are not effectively reducing their
relative risk of HIV infection.
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Based on the definition of “synergy” by Alsallaq et al. (2013), we determined
the levels of interaction between PrEP and condoms for both the assumptions
of positive and negative correlation between levels of condom use and the
acceptability of PrEP using the following formula:
synergy = (RRcondom ∗RRPrEP )−RRcombination. (4.4.2)
If “synergy” = 0, then there is no interaction between the prevention methods.
However, if “synergy” > 0, then the interaction between the prevention meth-
ods exhibits synergy and if “synergy” < 0, then the interaction is redundant.
The results of our calculations are in Table 4.3. For positive correlation,
we find that the interaction between condoms and PrEP are redundant for
males, females and in total. Although we find that PrEP and condoms inter-
act synergistically and thus complement each other in the prevention of HIV
transmission when we assume a negative correlation, the interaction is modest
with “synergy” values very close to zero.
Table 4.3: Results of the measure of “synergy” measuring the interaction
between condoms and PrEP when we assume positive or negative correlation
between condoms and the acceptability of PrEP, based on equation (4.4.2).
Correlation Assumption Males Females Total
Positive -0.056 -0.004 -0.023
Negative 0.045 0.022 0.026
4.5 Conclusion
In this Chapter we focussed on the impact of different prevention methods,
both individually and in various combinations of prevention methods, on HIV
incidence when we simulated a hypothetical randomized controlled trial. We
allowed for heterogeneity in levels of condom use, levels of acceptability of
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different prevention methods and levels of adherence to different prevention
methods, and the variation in local male circumcision norms and practices.
We accounted for correlation between the level of condom use and the level
of acceptability of other prevention methods, as well as a correlation between
the levels of acceptability of a prevention method and the levels of adherence
to the prevention method. We found that for females, the ring formulation of
vaginal microbicides had the greatest impact on HIV incidence, and for males,
offering both the MMC and PrEP resulted in a greater effectiveness than of-
fering either prevention method alone. Since the model sample size of 2000
individuals achieved a power value similar to that produced by the sample size
estimation function in the R statistical software package, we then determined
that the sample size required to achieve 80% power to detect statistical sig-
nificance is ∼1013 per arm. A sensitivity analyses demonstrated the impact
on HIV incidence when we assumed either a positive or a negative correlation
between the levels of condom use and the acceptability of other prevention
methods. The levels of interaction between condoms and PrEP only exhibited
synergy when a negative correlation between the levels of condom use and the
acceptability of PrEP was assumed.
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Conclusion and Discussion
The model developed here is a stochastic individual-based simulation. The
main aim of the model is to determine the impact of an HIV intervention
package on HIV incidence among adolescents participating in a hypothetical
trial, over a relatively short three year term. The package, consisting of medical
male circumcision, pre-exposure prophylaxis and antiretroviral-based vaginal
microbicides, both a gel formulation and a ring formulation, are only offered
to individuals in the intervention arm of the trial. All individuals are HIV-
negative and aged 15–18 years old at the start of the trial.
Although the prevention package that we are simulating is a fairly com-
prehensive package, the relative risk of HIV infection is estimated at only 0.54
(95% CI 0.52–0.55). The estimate for females is 0.57 (95% CI 0.56–0.58) and
the estimate for males is 0.51 (95% CI 0.49–0.53). For females, the relative risk
estimate when only offering the ring formulation of the vaginal microbicide is
the same as the full package, 0.57. The ∼40% reduction in HIV incidence is
not the massive impact we expected from such a comprehensive package.
Based on our model, in the case of the prevention package for females, we
found that the exclusion of the ring formulation of vaginal microbicides signif-
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icantly affected the mean relative risk of HIV infection. For males it is evident
that offering both the medical male circumcision and PrEP results in a greater
effectiveness than offering either prevention method alone. This suggests that
when developing a combination prevention package for adolescents, it will be
important to offer both MMC and PrEP to males, but it may be sufficient to
offer only a vaginal ring microbicide to females. However, the efficacy of the
vaginal ring approach to microbicide delivery has not yet been established, and
our model findings may need to be revised once vaginal ring trial data have
been published. Further investigations, such as cost-effectiveness analyses of
the prevention methods and more acceptability and adherence studies, will also
be important in determining which prevention methods are most appropriate
to exclude from a prevention package.
It is generally assumed that combination prevention methods would have
a greater impact on HIV incidence than would be expected with any single
intervention but we show that this is not necessarily the case. Our simulations
suggest that offering women a selection of different antiretroviral-based pre-
vention methods would not lead to any additional benefit over offering only
a vaginal ring, if vaginal rings would be substantially more acceptable than
other delivery methods. More options could result in a trade-off between ac-
ceptability and efficacy, as individuals may find a less effective option more
acceptable. Strategies that target acceptability, uptake and adherence issues
should be investigated.
When comparing our model results to other models, we first focus on the
impact of the individual prevention methods. Most studies that have mod-
elled the impact of male circumcision have suggested that over a 5–15 year
period it would reduce HIV incidence by 8–23% (Hallet et al., 2008; Londish
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and Murray, 2008; White et al., 2008; Williams et al., 2006). For example,
White et al. (2008) estimated that offering male circumcision to 15–49 year
old population over a ten year period would reduce male HIV incidence by
23%. Our model estimates a relatively large reduction in HIV incidence, 20%
over three years, when compared with these other studies. This is likely to
be because we simulated a hypothetical randomized controlled trial in which
there is a high rate of uptake, whereas these other models estimated a popula-
tion level impact. Our model allows for traditional male circumcision, as well
as variation in acceptability of medical male circumcision, which other models
have not allowed for.
Other studies that have modelled the impact of PrEP have found reduc-
tions in HIV incidence of 3.2–28% over an average of 5–10 years (Abbas et al.,
2007; Desai et al., 2008; Paltiel et al., 2009; Pretorius et al., 2010). This is
less than what our model estimated, a reduction of 34%. For example, when
targeting women aged 15–35 years old, Pretorius et al. (2010) estimated a
lower reduction in HIV incidence (10–25% over a period of ten years) if the
coverage of PrEP was between 30% and 60% of the population. Again, our
higher estimate is likely to be because we are simulating a randomized trial. A
model by Cremin et al. (2013), calibrated to KwaZulu-Natal data, estimates
a 3.2% reduction over ten years for 15–24 year olds, with 7.3% coverage. The
percentage reduction in HIV incidence for that population is roughly half the
coverage. Our model also suggests that the percentage reduction in HIV in-
cidence in youth is approximately half the PrEP coverage (72% coverage of
PrEP reduces HIV incidence in adolescents by 34%). However, the model by
Cremin et al. (2013) is taking into account the secondary benefits of PrEP;
i.e. that a person who is less likely to acquire HIV is less likely to transmit
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HIV. The effect of this over the short term is less substantial than over the
long term.
Our model estimates that the impact of the combination of both formula-
tions of the vaginal microbicides compared to the impact of the ring formu-
lation alone is the same, a reduction in HIV incidence of 43%. The impact
estimated for the gel formulation alone is 17%. Although our study assumes
the same efficacy for both the formulations, the difference in the impact of the
vaginal microbicides is due to the different assumptions regarding the levels of
acceptability of and the levels of adherence to the products. A model by Wil-
son et al. (2008) estimates the cumulative incidence reduction for females in
a resource-limited setting over a one year trial period of vaginal microbicides
to be 15% (IQR: 12–19%). This is thus comparable to the reduction esti-
mated for the gel formulation in our model but not the ring formulation. Most
other modelling studies only considered the impact of a single mode of deliv-
ery (Foss et al., 2003; Wilson et al., 2008; Karmon et al., 2003). What is new
in our study is that we have considered different forms of vaginal microbicide
administration.
When considering the combined impact of male circumcision and vaginal
microbicides, our model estimates a reduction in HIV incidence of 38%, with
an uptake of 46% for male circumcision and an uptake of 91% for vaginal
microbicides. The model by Cox et al. (2011) estimates that with similar
coverage of microbicides and male circumcision, HIV incidence would reduce by
35–40%, similar to our model. When estimating the impact of the combination
of male circumcision, PrEP and vaginal microbicides at a population level, the
model by Long and Stavert (2013) estimates that the combination would avert
43.5% of HIV infections over ten years. Our model estimates a similar risk
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reduction of ∼40% over a three year period. Both the Cox et al. (2011) and
Long and Stavert (2013) estimates are for a population level impact, whereas
our model estimates are within the context of a randomized controlled trial.
Our stochastic microsimulation allows for heterogeneity in behaviour among
adolescents. The model accounts for variation in local male circumcision norms
and practices (Connolly et al., 2008b; Mark et al., 2012). The model allows
for heterogeneity in levels of condom use (Pettifor et al., 2004a; Shisana et al.,
2009; Johnson et al., 2010), heterogeneity in the levels of acceptability and
uptake of prevention methods (Westercamp and Bailey, 2007; Ramjee et al.,
2010; Rosen et al., 2008; Altini et al., 2010; Guest et al., 2010; Heffron et al.,
2012; Lissouba et al., 2011) and heterogeneity in the levels of adherence to the
different prevention methods (Nel et al., 2011; Van der Straten et al., 2008;
Baeten et al., 2012). Most other models do not allow for this heterogeneity in
uptake and adherence.
When taking into account the correlation between the level of condom
use and the acceptability of other prevention methods, both a positive and
negative correlation was modelled. A negative correlation, meaning that ado-
lescents who have a high rate of condom use do not see the need to use any
other prevention method, was found to be associated with a greater prevention
programme impact. This illustrates the sensitivity of the model results to the
assumption about correlation and further research is required to understand
these correlation coefficients.
Correlation between the level of acceptability of a prevention method and
the level of adherence to the products is also modelled. A positive correlation
between the acceptability of and adherence to a microbicide has been shown
(Van der Straten et al., 2008). Although acceptability of prevention methods
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is strongly associated with younger ages (Eisingerich et al., 2012), adherence
is significantly higher at older ages (Marrazzo et al., 2013). This suggests that
the true association between acceptability and adherence may be confounded
by factors such as age. More investigations into acceptability, uptake and
adherence of different prevention methods among adolescents are needed, as
the level of adherence to a prevention method impacts the overall efficacy of
that prevention method (Abdool Karim et al., 2010; Grant et al., 2010; Baeten
et al., 2012).
An analysis was performed to determine the effect of different trial sample
sizes. Since power calculations are vital in determining the optimal sample
size required to achieve statistically significant results (Schulz and Grimes,
2005), the results of our analysis are important in deciding the appropriate
sample size when conducting a randomized trial. The model calculations of
the required sample size were roughly consistent with results obtained when we
used R statistical software. Our method for calculating the sample size takes
into account variability in HIV incidence rates across adolescent sub-groups,
yet produces a similar estimate of required sample size to that calculated in R,
which does not explicitly allow for heterogeneity in event rates. This suggests
that heterogeneity in HIV acquisition risk does not substantially compromise
the sample size estimation.
A complication affecting the design of the randomized controlled trial is
the need to provide the current standard of care. The standard of care pack-
age is a minimum for both the intervention and control arms (Bucher et al.,
1997; Miller and Silverman, 2004; Crepaz et al., 2006). Since medical male cir-
cumcision is already being scaled up nationally (South African National AIDS
Council, 2012), offering the option of medical male circumcision to partici-
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pants in the control arm could be regarded as part of the standard of care for
all participants. Should this happen, the model would then be overestimat-
ing the overall effectiveness of the prevention package for males. However, in
South Africa there is some controversy around the promotion of medical male
circumcision for adolescents (McQuoid-Mason, 2013), so it might not become
standard of care. Also, an important part of the intervention package might
be offering the various services in an adolescent-friendly environment, which
would increase uptake (this is not part of the current standard of care which
involves providing male circumcision in regular clinics that are not particularly
adolescent-friendly).
The model has a number of limitations. Firstly, the model was limited
in that no variation in the rate of HIV transmission per sex act was allowed.
Cervical ectopy (Myer et al., 2006) and pregnancy (Moodley et al., 2009) affects
the risk of male-to-female HIV transmission. Factors such as HIV viral load
(Attia et al., 2009), which impact the level of infectiousness, and other STIs,
which impact both the level of susceptibility and the level of infectiousness
(Boily et al., 2009), were not accounted for. The effect of antiretroviral therapy
on the level of infectiousness of the HIV infected partner (Attia et al., 2009;
Reynolds et al., 2011) has also not been accounted for. By not allowing for all
this variation caused by biological and behavioural factors (Chen et al., 2007),
we could be underestimating variation in HIV incidence rates and hence the
width of the 95% confidence intervals around the relative risk of HIV infection.
The true dynamics of relationships are complex (Morris and Kretzschmar,
1997; Delva, 2010; Epstein and Morris, 2011; Mah and Shelton, 2011) and
the model only allowed for a maximum of two concurrent partnerships for
individuals who were classified as high risk. The model did not allow for
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heterogeneity within a risk group. Thus all individuals in a particular risk
group were assumed to have the same behavioural characteristics, such as
rates of partnership formation and dissolution, over the trial period. The
heterogeneity in risk that we are not capturing could lead to the variability in
HIV incidence rates being underestimated and hence underestimation of the
sample size required. The association between risk group and HIV status, in
section 3.2.5, has also not been modelled.
In our model we have assumed that all adolescent virgins are HIV nega-
tive. This is probably unrealistic as there is increasing evidence of survival of
vertically-infected children into adolescence (Ferrand et al., 2009).
Another limitation of this analysis is that the variance assumptions for the
levels of acceptability and adherence were set arbitrarily. A review of data
on variation in the acceptability of and adherence to the different prevention
methods is required. Pilot studies are currently being conducted in South
Africa to assist with the estimation of these variance parameters.
Our model does not account for the possible impact of risk compensation.
Risk compensation, either a decrease in condom use or an increase in risk be-
haviour, has been shown to negatively affect the impact of prevention methods
on HIV incidence (Hallett et al., 2007; Van de Vijver et al., 2009; Cremin et al.,
2013; Abbas et al., 2007; Supervie et al., 2010; Eaton and Kalichman, 2007).
Although most of the RCTs have not shown evidence of risk compensation, one
would not expect to see much risk compensation when subjects are blinded to
their assignment to the intervention/control arm. In the intervention trial we
are evaluating, subjects would know which products they are using and how
effective they are, and the likelihood of risk compensation would thus be much
greater.
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In setting the initial HIV prevalence assumptions, we used data from the
2003 loveLife survey (Pettifor et al., 2004a). It is important to note that the
HIV prevalence in youth has declined since the time of the 2003 loveLife survey,
and the data could thus be an overestimate of the current HIV prevalence.
However, the survey was nationally representative and our model population is
a sub-population representing a relatively high risk group. Since we anticipate
the trial participants would be recruited mostly from informal settlements
where the HIV risk and prevalence is much higher, the loveLife survey estimates
could also be underestimates of the HIV prevalence. Thus these biases may
cancel each other to some extent.
There is much uncertainty regarding the acceptability, efficacy and adher-
ence parameters, especially for the vaginal ring which has not yet been proven
efficacious. The model is limited in that we did not do a formal uncertainty
analysis. This was mostly due the very long run time of the simulations in R.
One simulation, consisting of 1000 trials with 2000 participants per trial, would
take approximately a day to run. Running more than one simulation at a time
would occasionally freeze the computer system. The runtime was also affected
by the specifications of my laptop, an Intel Pentium®Dual CPU T3400 / 2.16
GHz with 2.9G RAM. It may be necessary to explore uncertainty analysis tech-
niques that have recently been developed for microsimulation models, which
take account of the long run times typically associated with microsimulation
models (O’Hagan et al., 2007).
The model is a static model, and all the model assumptions are fixed, due
to the short three year duration of the hypothetical trial period. Further work
is required to extend the model from a simulation of a hypothetical random-
ized trial to a model of the impact that a combination prevention package may
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have when introduced at a population level. The extent to which adolescents
interact with the adult population needs to be accounted for (Chapman et al.,
2010), as well as the extent to which adherence to different prevention methods
is sustained as adolescents enter into adulthood. Another reason for extending
the model to the rest of the population is that it allows us to quantify the
primary prevention benefits of the intervention (i.e. with earlier diagnosis of
adolescents with HIV, we can quantify the impact of changes in their sexual
behaviour once diagnosed). Even if PrEP and microbicides prove to be safe
and efficacious, concerns regarding their effective implementation include ad-
herence and related drug resistance concerns (Supervie et al., 2010; Van de
Vijver and Coucher, 2010). In addition, the increasing use of tenofovir in first-
line ART, and the potential for rising tenofovir resistance due to poor ART
adherence, has important implications for the effectiveness of tenofovir-based
prevention methods. Including the impact of drug-resistance in the extended
model could address this issue.
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